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Abstract 
 
 
 
Interactions of mtFabH with its substrates and inhibitors reveal novel 
mechanistic insights 
By Sarbjot Singh Sachdeva, Ph.D. 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy  
at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2007 
 
Major Director:  Kevin A. Reynolds 
Professor, Department of Medicinal Chemistry (former)  
Professor and Chairman, Department of Chemistry, Portland State University (current) 
 
 
Tuberculosis emerged from its grave to be one of the deadliest diseases of the 
present time after recently developing a synergy with AIDS. A fatty acid condensing 
enzyme-mtFabH has been proposed to connect the key processes involved in biosynthesis 
of mycolic acids, an important component of mycobacterial cell wall. It condenses long 
acyl Coenzymes A (CoA; up to C20CoA) with malonyl Acyl Carrier Protein (ACP) to 
form the elongated β-ketoacyl-ACP which further undergoes rounds of elongation to 
form mero-mycolate branch of mature mycolic acids. Owing to its proposed central 
position in mycolic acid synthesis, mtFabH has attracted considerable attention as a good 
anti-mycobacterial target. 
   
  
xvii
In this study, we utilized important biochemical tools such as site directed 
mutagenesis, mass spectrometry and X-ray crystallography to address some of the key 
unanswered questions regarding the intricate workings of mtFabH. We solved the first 
co-crystal structure of substrate C12CoA with mtFabH and further analyzed the substrate 
specificity of this acylation step. This structure depicts the mode of acyl-CoA binding in 
mtFabH channels; and its comparison with the parallel E.Coli-acetyl CoA structure 
provides important similarities and differences in substrate binding in these two FabH 
enzymes. It also posed an important question about the trajectory of long acyl chain CoA 
into the deep and “seemingly closed” substrate binding pocket of mtFabH. By utilizing 
disulfide-based inhibitors, we showed that large conformational changes are necessary to 
facilitate ligand trafficking in mtFabH while the high catalytic turnover rate of the 
enzyme is maintained. We also proposed the most likely location of the involved loop. 
A much faster and less cumbersome assay for mtFabH was also developed and it 
was utilized to characterize a series of inhibitors. This assay utilizes the commercially 
available radioactive malonyl-CoA in lieu of malonyl-ACP, the physiological substrate, 
and thus can serve as ACP independent assay for mtFabH. 
These studies further our understanding of the biochemistry of mtFabH, which 
along with the faster assay could be helpful in designing potent mtFabH inhibitors as 
anti-tubercular agents in the future.  
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1. Introduction 
 
1.1 Tuberculosis: a global burden 
Tuberculosis is one of the deadliest diseases of the present time: one third of the 
world’s total population - approximately two billion people - is currently infected with it, 
and it causes more deaths than any other single infectious disease.1 According to the 
World Health Organization (WHO), about eight million people develop active TB every 
year and close to two million die from it.2 It is estimated that by the end of year 2020, 
nearly one billion new infections will be reported; of those, about 200 million people will 
have active TB and about 70 million will die from it, if new and improved treatments are 
not introduced.3,4 
TB is caused by mycobacteria of ‘tuberculosis complex’ primarily 
Mycobacterium tuberculosis, but also Mycobacterium bovis and Mycobacterium 
africanum. This highly contagious disease is transmitted through the air by inhalation of 
infective droplet nuclei spread by sneezing, coughing, talking or spitting, and it infects 
lungs, brain, spinal cord, bones, and joints and various other organs. The rod shaped, 
acid-fast TB bacillus invades the lungs through the air canal from where it may spread to 
various other parts of the body through the blood stream, if left untreated. Development 
of anti-tubercular drugs such as isoniazid, rifampicin, ethambutol and pyrazinamide led 
to the near-eradication of TB two decades ago but recent emergence of HIV/AIDS and its 
   
  
2 
synergy with TB has caused the resurgence of TB on a much larger scale than ever, 
especially in developing countries (Figure 1). In 1993, the gravity of the problem led 
WHO to declare TB as a global emergency in an attempt to heighten political and public 
awareness. TB is the leading killer among HIV-infected persons, because they have 
weakened immune systems, with quarter million TB deaths being HIV-related.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A further complicating factor that has resulted in the rise of TB is emergence of 
new strains of M. tuberculosis which are resistant to one or more current anti-tubercular 
drugs (Multi Drug Resistant TB or MDR-TB).5,6 According to a recent survey by WHO 
Figure 1: The estimated incidence rates of tuberculosis in different parts of the world in the year 
2003. The data is reported by World Health Organization (WHO) and numbers are given per 100,000. 
   
  
3 
and its partners, MDR-TB is present in all of the 109 countries surveyed.1 Multiple 
reasons have been associated with the development of this resistance by the TB bacillus, 
including patient’s non-compliance with treatment, prescription of incorrect treatment, 
unreliable drug supply, or inconsistent or incomplete treatment.7 The current revised TB 
treatment recommended by World Health Organization (WHO) is a 6-8 month ‘short’ 
therapy with a frontline anti-tubercular drug cocktail consisting of isoniazid, rifampicin, 
ethambutol, pyrazinamide and streptomycin specifically implemented by the DOTS 
program (Directly Observed Treatment, Short course).1 Extensive research is underway 
in many federal, academic and industrial laboratories to explore new targets and drugs to 
fight this growing global problem. 
 
1.2 Mycobacteria: the Fort Knox of bacteria 
The exceptional pathogenicity and virulence of TB bacteria are largely associated 
with its formidable cell wall,8-10 a very unique structural feature of the Cornyebacterium-
Mycobacterium-Nocardium (CMN) branch of Actinomycetes order, to which M. 
tuberculosis belongs. This unusual and highly hydrophobic mycobacterial cell wall is 
composed of three main structural components: arabinogalactan, peptidoglycan and the 
hallmark of mycobacteria, mycolic acid (Figure 2). These three components are 
covalently linked (thus often referred to as mycolyl-Arabino-Galactan-Peptidoglycan 
complex or mAGP) and provide the basic framework of the mycobacterial cell wall.11 
Mycolic acids, in particular, are of special interest because of their unique chemical 
structure and their highly lipophilic nature, which primarily regulates the permeability of 
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the mycobacterial cell wall.12,13 The importance of mycolic acid is evidenced by the fact 
that it comprises 60 % of the weight of the cell wall.14  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mycolic acids are high molecular weight α- alkyl β- hydroxy fatty acid (C50-C90) 
that are found either covalently attached to the mycobacterial cell wall in the form of 
Figure 2: Schematic representation of the mycobacterial cell wall. A layer of peptidoglycan 
encapsulates the plasma membrane and is covalently linked to mycolyl-arabinogalactan by an unusual 
disaccharide phosphate bond. The mycolic acid chains are shown perpendicular to the plasma membrane 
and the exposed portion is seen interacting with trehalose dimycolate, the extractable lipids of 
mycobacterial cell wall. 
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mAGP or non-covalently as in trehalose dimycolates, the so-called extractable lipids. 
They form a thick, robust lipid layer on the mycobacterial cell wall and perform a myriad  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
of gate keeper functions such as protecting the bacteria from the toxic external 
environments of the host immune system8,15,16 and commonly used antibiotics.17 The 
Figure 3: Various types of mycolic acids found in M. tuberculosis. α-Mycolates are the most 
abundant mycolic acid type (~57%) in M. tuberculosis and its mero chain contains two cis-
cyclopropanes. Methoxymycolates, the second most abundant class of mycolic acid in M. tuberculosis 
(~32%), contain an a-methyl methyl-ether moiety in the distal position and a cis-cyclopropane or an 
α-methyl trans-cyclopropane in the proximal position. Ketomycolates, which are less abundant 
(~11%), contain an a-methyl ketone moiety in the distal position and proximal functionalities as in the 
methoxy series. (Adopted from ref. 27) 
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alkyl chains of mycolic acids are species-specific with the α-alkyl branch ranging from 
22-26 carbons and the long meromycolic acid ranging from 50-63 carbons. M. 
tuberculosis contains the longest alkyl branches in its genera with an α -branch up to 26 
carbons and meromycolic acid arms up to 63 carbons. The meromycolic arm of mycolic 
acids is further functionalized by a combination of unsaturation, cyclopropanation and 
oxygenation (Figure 3). These are proposed to impart and regulate various important cell 
wall properties of mycobacterium, such as fluidity and anchoring to the host cell surface 
molecules, thereby defining its role in survival and pathogenesis.13,18,19 These unique 
properties, conferred only by mycolic acids, make TB bacilli one of the toughest disease 
opponents ever faced by mankind. 
 
 1.3 Mycolic Acid and Fatty Acid Biosynthesis  
The backbone of mycolic acids, the shorter alpha branch and the longer 
meromycolate alkyl chains, are synthesized by the ubiquitous and well-characterized 
Fatty Acid Synthases (FAS). Fatty acid biosynthesis, an essential process in all 
organisms, is catalyzed by two distinct systems, Type I in mammals and fungi20 and Type 
II in plants and bacteria21 (Figure 4). The Type I FAS system is characterized by one (in 
mammals) or two (in fungi and Corynebacterium ammoniagenes) polypeptide chains 
containing multiple domains, which catalyze all of the different steps of the FAS cycle. 
These polypeptides include the Acyl Carrier Protein (ACP), which ferries the growing 
acyl chain from one domain to another. In the Type II system, each FAS reaction is 
carried out by a discrete enzyme encoded by an individual gene. 
   
  
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: The organization of fatty acid biosynthesis in Type I (a) and Type II FAS (b): (a) In 
mammals, a single multifunctional polypeptide complex (existing as a dimer) performs fatty acid 
biosynthesis and the growing acyl chain remains bound until chain elongation is complete.  (b) In 
bacteria, each of the FAS II reaction is performed by discrete proteins and the pathway 
intermediates are ferried from one specific protein to the next as thioester derivatives of acyl carrier 
protein (ACP). The figure in bracket (e.g. 2C) denotes the length of the carbon chain. (Adopted from 
ref. 23) 
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The intermediates in a Type II FAS are carried from one enzyme to another by a discrete 
acyl carrier protein (ACP). The various reactions carried out by the Type I and Type II 
FAS system are essentially the same in spite of their organizational differences.22,23 In 
general, transfer of the acyl moiety from acyl coenzyme A (CoA) to the active site 
cysteine of ketosynthase III (FabH), followed by condensation with malonyl-ACP to 
form the β-ketoacyl-ACP product, is the reaction that initiates the FAS process.  The 
analogous ketosynthases, FabB and FabF, which take up acyl ACP in place of acyl-CoAs 
as substrate, catalyze subsequent condensation reactions. Malonyl-ACP is derived from 
the transfer of a malonyl group from malonyl-CoA to ACP catalyzed by the enzyme 
malonyl-CoA: ACP transferase or FabD. After each condensation step, the growing β- 
ketoacyl product is converted into acyl-ACP by the sequential enzymatic action of β-
ketoacyl-ACP reductase (FabG), β-hydroxyacyl ACP dehydrase (FabA or FabZ), and an 
NADH-dependent enoyl ACP reductase (FabI) (Figure 5). 
 Mycobacteria are distinct from other bacteria because they possess both Type I 
and Type II fatty acid biosynthesis systems.24,25 The type I FAS of mycobacteria is 
responsible for the de novo production of the α- branch of the mycolic acid as well as the 
meromycolate “primer” acyl chain that is further elongated by the type II FAS system. A 
key regulatory enzyme termed mtFabH or ketoacyl-synthase III (KAS III) forms the 
pivotal link between the last cycle of FAS I and the first cycle of FAS II systems in M. 
tuberculosis.26,27 mtFabH preferentially catalyzes the condensation of C16/C24 acyl-CoA 
(released from FAS I) and malonyl-ACP to form the corresponding β-ketoacyl-ACP 
product, which is further taken up by the Type II FAS system of mycobacterium and
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Figure 5: The bacterial type II FAS pathway depicting the general reactions of fatty acid biosynthesis. The organization of Type I and 
Type II FAS is different as shown in figure 4 but the nature of reactions carried out by both systems are essentially the same. First, Acetyl-CoA 
(Ac-CoA) is carboxylated by heterotetrameric AccABCD to form malonyl-CoA which is then tranferred to ACP by enzyme FabD. Fatty Acid 
Biosynthesis is catalyzed by iterated cycles of condensation (FabH, FabB, FabF), reduction (FabG), dehydration (FabA or FabZ) and reduction 
(FabI or FabK) steps as shown above. (Adopted with modifications from ref.22) 
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elongated to C24-C63 carbon meromycolates. Finally, these meromycolates are condensed 
with the shorter (C23-C26) alpha alkyl chain from FAS I to form mature mycolic acids 
(Figure 6).28  
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Figure 6: Importance of mtFabH in fatty acid elongation and mycolic acid biosynthesis in M. tuberculosis. The fatty acids produced by the type 
I synthase are removed from the complex by an unidentified transacylase yielding long-chain acyl-CoAs. These acyl-CoAs are used either for alpha 
branch of mature mycolic acids or by mtFabH, which initiates a round of elongation by the type II Synthase that eventually produces the 
meromycolate branch of mycolic acids. The shorter alpha branch from FAS I and the longer meromycolate from FAS II condense to form mature 
mycolic acids, which are incorporated into the cell wall. 
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1.4 Mycolate biosynthesis: the target of current anti-tubercular drugs  
Mycolic acid, due to its incredible chemical structure and crucial role in 
mycobacterial virulence and impenetrability, has always been a very important target in 
anti-mycobacterial drug design. Many of the currently used and highly effective anti-
tubercular drugs inhibit fatty acid biosynthesis involved in synthesis of alkyl chains of 
mature mycolates, thus validating the suitability of mycolate and fatty acid biosyntheses 
as excellent drug targets.29 Important anti-tubercular drugs, which act by inhibiting one or 
more components of FAS in TB bacteria, are shown in Figure 7 and clinically relevant 
drugs are discussed in detail below. 
 
1.4.1 Isoniazid (INH) 
Isoniazid (INH or isonicotinic acid hydrazide) was first discovered as an anti-
tubercular drug in 1952 and since then it has been used clinically as a frontline drug of 
choice for treatment of tuberculosis. Both M. tuberculosis and M. bovis were found 
susceptible to INH with a MIC range of 0.02 –0.2 µg/ml. INH acts as a bactericidal agent 
by causing bacterial lysis within twenty four hours of its treatment. Although the drug 
had been known to block mycolic acid biosynthesis,30-33 the precise enzymatic target and 
thus the mechanism of action of INH remained elusive for over forty years. In 1994, for 
the first time, Banerjee et al34 traced the target of INH to be a product of the structural 
gene inhA, which was later found to code for an NADH-dependent FAS II enoyl-ACP  
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Figure 7: Structures of various anti-mycobacterial agents: Anti-tubercular agents, 
which inhibit one or more components of mycolic acid biosynthetic pathway. 
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reductase in M . tuberculosis termed InhA (equivalent to FabI of E. coli). However, with 
the finding that another fatty acid enzyme – the condensation enzyme KasA (an E. coli 
ketoacyl-synthase I equivalent) of type II FAS in M. tuberculosis – is also bound to a 
INH-ACPM complex and therefore a potential target of INH,35 it is currently debated 
whether INH may have more than one target in M. tuberculosis. Moreover, a non-FAS 
enzyme, dihydrofolate reductase (DHFR) of nucleic acid biosynthesis, has also recently 
been proven to be inactivated by INH and is thus also claimed to be a physiological target 
of INH.36 Probably the success of INH all these years was, in fact, due to its inhibition of 
more than one enzyme, which has made it difficult for bacteria to develop resistance 
against it. 
 
1.4.1.1 Isoniazid: mechanism of action and resistance development  
INH is shown to be a prodrug in M. tuberculosis: it requires activation by an 
oxidizing enzyme, KatG peroxidase, to be converted into its active intermediate as shown 
in Figure 8. It is proposed that INH is first oxidized by KatG peroxidase to produce the 
highly reactive intermediate 1 or 2 (isonicotinic acid anion or a free radical), which then 
reacts respectively with either NAD+ or NAD˙ (in the absence of KatG) to form the INH-
NAD adduct. This final electrophilic adduct is shown to bind and inhibit InhA at a 
nanomolar range37 and is also most likely the species involved in inhibition of KasA. The 
idea that the activated adduct formed between INH and NAD+ could possibly attack any 
of the cellular NADH dependent enzymes has, at least theoretically, fostered the belief  
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1 2 
Figure 8: Proposed pathway for formation of the isonicotinic acyl-NADH inhibitor of InhA. Two 
possible scenarios are shown, in which an activated form of isoniazid (isonicotinic acyl anion or radical) 
covalently attaches to a form of NADH (NAD1 or NAD. radical) within the active site of InhA, while 
retaining a tetrahedral carbon at position four of the nicotinamide ring. (Adopted from ref. 37) 
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that more than one NADH-dependent enzyme could be a target for INH. Although INH 
resistance has been shown to correlate to mutation or deletion in the KatG gene in at least 
50% of clinically resistant M. tuberculosis strains,38 analysis of all available resistant 
strains suggests potential involvement of at least four other genes, including KasA and 
inhA.6 The number of total enzymes involved in INH inhibition and the extent of 
inhibition is currently debatable, but all evidence so far inarguably maintains that InhA is 
the major target of INH. 
 
1.4.2 Pyrazinamide (PZA) 
Pyrazinamide (PZA) was discovered in 1952 in an attempt to find more potent 
analogs of nicotinamide, a compound found to have weak anti-tubercular activity. But 
unlike isoniazid, pyrazinamide was not used extensively in treatment of TB until the mid-
1980s. The later finding that PZA exerts strong synergistic and accelerating effects on 
other anti-tubercular drugs has resulted in its current recommendation in every 
combination therapy for the treatment of the disease. The MIC of PZA varies from 8-60 
µg/ml depending on the assay method and media employed.39 It is found to be active 
against M. tuberculosis, but not against M. bovis and other rapidly-growing 
mycobacterial species. 
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1.4.2.1 Pyrazinamide: Mechanism of action and resistance development 
Like INH, pyrazinamide is also a pro-drug that requires amide hydrolysis by 
mycobacterial pyrazinamidase (a nicotinamidase) to convert to pyrazinoic acid, its active 
form.40 This mechanism of activation is evidenced by the fact that pyrazinoic acid and its 
various analogs were found to have at least equivalent or better activity against clinically 
resistant strains of M. tuberculosis and naturally resistant strains of M. bovis, which lacks 
pyrazinamidase activity.41,42 After activation, PZA is found to exert its anti-tubercular 
effect by inhibiting the Type I FAS multifunctional enzyme in M. tuberculosis with no 
effect on Type II enzymes. PZA inhibits [C14] acetate incorporation into C16-C24/C26 fatty 
acid whereas [C14] palmitate incorporation into mycolic acid is unaffected, strongly 
suggesting that type I FAS is indeed the target; interestingly, however, PZA does not 
block mycolic acid synthesis, which raises important doubts about its mode of action. 
Resistance against PZA is shown to be related to loss of pyrazinamidase activity in M. 
tuberculosis.  
 
1.4.3 Miscellaneous inhibitors 
Apart from the WHO-recommended frontline anti-tubercular drugs INH and PZA, 
several  second-line drugs including ethionamide, thioacetazone, and thiocarlide (isoxyl) 
have been shown to exert anti-tubercular activity via the proposed inhibition of one or 
more components of mycolic acid biosynthesis (see Figure 7). Also well known 
antibacterials like triclosan and cerulenin are also proven to exert their inhibitory effect 
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by acting on one or more enzymes of fatty acid biosynthesis in bacteria. Thus, there is 
ample evidence available that mycolic acid biosynthesis is an excellent drug target. 
A relatively newer addition to the anti-tubercular drug list is the compound PA-
824 which also shows significant activity against the clinically resistant TB strains.43,44 
PA-824, a 3-substituted nitroimidazopyran, was initially discovered for cancer treatment 
and has been shown to possess highly specific activity towards M. tuberculosis complex 
by possibly inhibiting mycolic acid biosynthesis and protein synthesis. It is now widely 
touted as the next potential TB drug, as it has shown great promise in pre-clinical trials. 
PA-284 is also proposed to be a pro-drug based on the available data, but its exact nature 
of inhibition and physiological target are still unclear.45 
Thiolactomycin (TLM), a unique thiolactone antibiotic produced as a secondary 
metabolite of the soil fungi Nocardia sp., has been shown to have potent anti-microbial 
activity against several pathogens46-48 including the saprophytic strain Mycobacterium 
smegmatis mc2155 and the virulent strain M. tuberculosis Erdman.49 It blocks the Type II 
fatty acid synthase system in M. tuberculosis by inhibiting two key FAS condensing 
enzymes, ketoacyl synthase I (KasA) and III, both in-vitro and in-vivo; this ultimately 
leads to blockage of mycolic acid biosynthesis and cell death.49,50 These findings have 
encouraged the synthesis of a series of TLM analogs, many of which were found to be 
more potent than their parent compound TLM.51-54 
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1.5  mtFabH as an emerging anti-tubercular target 
Over the last decade, the resurgence of TB has created the necessity to find novel 
anti-tubercular targets and drugs. Key anti-tubercular drugs including frontline drugs like 
isoniazid (INH) and pyrazinamide (PZA) have been found to exert inhibitory action by 
blocking the synthesis of fatty acid, which corroborates the validity of FAS enzymes as  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Sequence alignment of FabH from E. coli, S. glaucescens, and M. tuberculosis. Positions of 
inserts in the latter two sequences are based on comparison of tertiary structures, not on sequence 
similarity, and are numbered with extensions to the residue number just preceding the insert. Boxed 
residues are a-helix present in mtFabH and missing in ecFabH and the putative specificity determinant at 
residue 87 (see figure 11 for detail). Asterisks denote active-site residues. (Adopted from ref.27) 
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targets for the development of novel anti-tubercular drugs. What makes mtFabH unique 
from other FAS enzymes is its capacity to link the two indispensable FAS systems; the 
enzyme thus plays a key role in mycolic acid biosynthesis in M. tuberculosis. Moreover, 
the absence of a human homologue of FabH has helped it garner significant interest as an 
anti-tubercular target and considerable effort is being directed at understanding its 
detailed mechanism by researchers around the globe. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Comparison of backbone folds for ecFabH (blue) and mtFabH (bronze) dimers. The 
insert at position 202 in mtFabH relative to ecFabH and the contiguous α-helix (cylinder) immediately 
preceding this insertion in mtFabH are colored red. The arrow indicates the non-crystallographic 2-fold 
axis defining the functional mtFabH dimer. (Adopted from ref. 27) 
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mtFabH is one of three condensing enzymes found in the type II FAS system of M. 
tuberculosis.   
This approximately 70 kD homodimer is encoded by the open reading frame 
Rv0533c (fabH ~ 1005 bp) of M. tuberculosis (H37Rv) chromosomal DNA and found to 
have high sequence similarity to its E. coli (ecFabH) and S. glaucescens (sgFabH) 
homologues (Figure 9). 26,55,56The closely related FabH enzymes, mtFabH and ecFabH, 
are seen to have the same core structure (figure 10) with the same characteristic buried 
Cys-His-Asn catalytic triad and the coenzyme-A/ACP binding channel; but unlike 
ecFabH, mtFabH takes up longer acyl-CoAs (C6 – C20) (Table 1), which is consistent  
 
Acyl-CoA  mtFabH (with ecACP) mtFabH (with ACPM) ecFabH 
     
   
Enzymatic activity (pmoles/min/ug)        (* 103) 
     
Acetyl CoA (2:0) n.d. n.d. 50.5 +/- 4.5 
Butyryl CoA (4:0) n.d. n.d. 5.30 +/- 0.20 
Isovaleryl CoA (5:0) n.d. n.d. 3.80 +/- 0.02 
Hexanoyl CoA (6:0) 0.39 +/- 0.07 1.74 +/- 0.07 3.40 +/- 0.60 
Octanoyl CoA (8:0) 5.98 +/- 0.19 5.49 +/- 0.93 n.d. 
Decanoyl CoA (10:0) 6.34 +/- 0.49 6.16 +/- 0.24 n.d. 
Lauroyl-CoA (12:0) 8.01 +/- 1.07 7.24 +/- 0.18 3.30 +/- 0.20 
Myristoyl CoA (14:0) 2.24 +/- 0.10 9.46 +/- 0.41 n.d. 
Palmitoyl CoA (16:0) 1.33 +/- 0.10 9.27 +/- 0.56 n.d. 
Stearoyl CoA (18:0) 0.60 +/- 0.10 10.39 +/- 0.51 n.d. 
Arachidoyl CoA (20:0) 0.06 +/- 0.02 9.02 +/- 0.0.27 n.d. 
 
 
 
 
 
 
Table 1: Substrate specificity of mtFabH (with homologous and heterologous ACP) and ecFabH 
towards various acyl-CoAs. For mtFabH specificity, the β -hydroxyacyl-ACP (either ec-ACP or mtACP) 
product formed is reduced with sodium NaBH4 and extracted with toluene and counted with liquid 
scintillation counter. For ecFabH specificity, enzyme activity was determined using 50 mM acyl-CoA, 7 
mM malonyl- ACP, 100 mM  NADPH, 1.5 mg S. pneumoniae FabG and 5 ng of E. coli FabH. The FabH-
FabG spectrophotometric-coupled assay was used to determine the substrate specificity of E. coli FabH for 
various acyl-CoA primers. In the coupled assay malonyl-ACP and acyl-CoA are condensed by E. coli FabH 
to yield β-ketoacyl-ACP, which is a substrate of S. pneumoniae FabG. FabG catalyzes the reduction of β-
ketoacyl-ACP to β -hydroxyacyl-ACP and the concomitant oxidation of NADPH to NADP+, a coupled 
reaction which was be monitored spectrophotometrically at 340 nm. (n.d.- Not determined) 
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Figure 12: Magnified view of the distal end of the myristoyl-binding site in mtFabH at the junction 
of the inserts of each monomer. The insert and preceding α-helix are shown in red, and the modeled 
myristoyl group (Ma and Mb in each subunit) is shown in lavender. Note the space in the FabH binding 
site for two more carbons on the end of myristoyl. (Adopted from ref. 27)  
Figure 11: Modeled position of the myristoyl group in binding channel 2 showing the position of 
residue 87B, which is a threonine in mtFabH (blue) and a phenylalanine in ecFabH (green). Residue 
87 is proposed to contribute to fatty acid chain length specificity for these two enzymes. (Adopted from ref. 
27) 
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with its role of extending the type I FAS acyl-CoA products. The preference for a longer 
acyl chain in mtFabH is proposed to arise from the presence of permissive Thr87B 
(compared to Phe87B in E. coli) which opens up the putative acyl channel in mtFabH to 
accommodate the longer acyl group (Figure 12). In the homologous sgFabH, the presence 
of identical Thr87B (Figure 9) and the relaxed substrate specificity relative to ecFabH fully 
support this hypothesis.55 The acyl chain length specificity for mtFabH was proposed to 
be limited to a maximum of C16CoA due to the positioning of a steric cap produced by 
the alpha helix at positions 194-202 on the acyl channel (see Figures 9 and 13). This 
maximal chain length effect was later seen to be the result of the heterologous ACP 
(ecACP) used in the study, as the utilization of homologous ACPM resulted in efficient 
condensation of physiologically relevant substrates (up to C20-CoA) (Figure 11).57  
 
1.5.1 Mechanism of the mtFabH reaction 
mtFabH is proposed to utilize C16 - C20 acyl-CoAs produced by the Type I FAS 
system and condenses them with malonyl-ACPM by a multi-step ‘ping-pong’ mechanism 
to form the corresponding two-carbon-longer β-ketoacyl-ACP product (Figure 14). The 
first step is the formation of an acyl-mtFabH intermediate by the attack of Cys112 
thiolate of mtFabH on the carbonyl carbon of the first substrate acyl-CoA 
(transacylation). In the subsequent step, CoA is released and the second substrate 
malonyl-ACP binds in the same pocket and decarboxylates to produce a carbanion. This 
carbanion then attacks the electrophilic acyl carbonyl of acyl-mtFabH to form the final β-
ketoacyl-ACP product (condensation) which is released to recycle the free mtFabH. This 
   
  
24 
long-chain β-ketoacyl-CoA product is then processed by the Type II FAS in M. 
tuberculosis to form the mature meromycolate chains.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Mechanism for the mtFabH catalyzed initiation of fatty acid biosynthesis. The acyl-
CoA depicted here is lauroyl CoA (12:0) which is elongated by 2 carbons provided by malonyl 
moiety attached to ACPM. 
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1.6 Thesis objectives 
The discovery of mtFabH and its proposed pivotal role in M. tuberculosis functioning 
has instigated significant interest in this enzyme, and the recent unraveling of the mtFabH 
structure has provided important preliminary structure-function insights into this enzyme. 
Some very crucial and relevant questions, however, still remain unanswered. Also, the 
lack of an easier and more efficient assay format to test potential inhibitors for this 
enzyme constitutes a serious roadblock to development of a specific inhibitor. Thus, we 
directed our efforts towards investigating different mechanistic aspects of the enzyme 
using various ligands; the long-term goal and future prospects were to discover novel, 
potent, and selective inhibitors of mtFabH. The specific aims in these regards were as 
follows: 
 
1. Development of an easier and relatively faster assay format to aid in discovery of 
potential inhibitors of mtFabH. The previous mtFabH assays require cumbersome 
washing steps, expensive scintillation proximity beads or the tedious preparation of 
biotinylated acyl carrier proteins. These factors are an impediment to the faster 
screening of potential inhibitors and thus a more efficient assay format should 
expedite their discovery. Here, we describe a much faster and less cumbersome 
mtFabH assay that directly utilizes commercially available substrate malonyl-CoA (in 
place of Malonyl-ACP) and thus overcomes the above mentioned disadvantages 
associated with previous methods. 
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2. Evaluation of the acyl binding pocket of mtFabH: The unique acyl binding pocket 
of mtFabH has been speculated but not proven to be responsible for its different 
substrate specificity compared to homologous ecFabH. Thus, we co-crystallized the 
Michaelis Complex between mtFabH and the first substrate acyl-CoA to evaluate its 
binding mode in the putative channels and to further compare it with the available 
ecFabH-acetyl-CoA co-crystal structure. This structural comparison should aid in 
design and development of effective inhibitors for these enzymes.  
3. Probing the reactivity and substrate specificity of both monomers of the 
mtFabH: The slower acylation rate relative to overall rate of condensation reaction 
for mtFabH reported by Besra et al. poses a question-mark on proposed functional 
equivalency between the two subunits of mtFabH. Also it further points towards a 
more involved (complex) role of cognate ACPM in the overall reaction. Here, we 
have utilized a mixture of C6-C20 CoAs and decyl-CoA disulfide to investigate the 
reactivity and substrate specificity of individual monomers of the mtFabH dimer. The 
results indicate a role of ACPM in priming and/or offloading of 3-ketoacyl ACPM 
product.  
4. Separate entrance and exit portals for ligand traffic in mtFabH: The unique 
substrate specificity of mtFabH and other downstream M. tuberculosis FAS II 
enzymes such as InhA and MabA for longer acyl-CoAs and ACPs poses an 
interesting question of large ligand trafficking in these enzymes. We utilized a series 
of disulfide-based inhibitors and a mtFabH mutant (whose pantotheinate binding 
channel is blocked by A246F mutation) to investigate the entry/exit of large ligands 
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to/from the deep and seemingly restricted mtFabH binding sites. We utilized mass 
spectrometry and x-ray crystallographic studies to provide the experimental support 
for an alternate route/conformation for ligand trafficking in mtFabH. This is a first for 
the FabH class of enzymes, especially for mtFabH, and could be a key to 
understanding the molecular interactions preceding the formation of the first mtFabH-
ligand complex and also following the product formation. 
5. Analysis of potential new mtFabH inhibitors: A series of FabH inhibitors have 
been identified for E. Coli and Plasmodium Falciparum FabH by techniques such as 
in-silico screening and chemical database searches. These inhibitors were evaluated 
for their activity against mtFabH and attempts were made to analyze the basis of 
inhibition against FabH class of enzymes.    
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2. Development of Mycobacterium tuberculosis β-Ketoacyl-Acyl Carrier 
Protein Synthase III (mtFabH) assay 
 
2.1 Summary 
The enzyme β-ketoacyl-ACP synthase (KAS III or FabH) is the key enzyme that 
initiates fatty acid biosynthesis in a type II dissociated FAS. It catalyzes the condensation 
of acyl-CoA and malonyl-ACP to form a β-ketoacyl-ACP product that is further 
processed to form mature fatty acids that are involved in various essential cellular 
processes like phospholipid biosynthesis, cell wall formation, etc. Herein described is a 
new assay for the Mycobacterium tuberculosis FabH (mtFabH) enzyme involved in a key 
initiation step in the synthesis of mycolic acids, which are an integral component of the 
cell wall. The assay eliminates the need for the cumbersome washing steps, specialty 
scintillation proximity assay beads, and the preparation of acyl carrier proteins, required 
in other assay formats. This discontinuous assay involves the reduction of radiolabled 
long chain β-ketoacyl-CoA product to its di-hydroxy derivative, which partitions into a 
non-polar phase for quantitation, while the reduced radiolabeled substrate derivative 
remains in the aqueous phase.  
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2.2 Introduction 
The most commonly used and established method to assay FabH involves the use 
of radioactive acyl-CoA and malonyl-ACP to form a radioactive β-ketoacyl-ACP 
product. This radioactive protein (ACP) product can be precipitated with acid, washed 
and counted, while the radioactive substrate stays in the aqueous phase. The accuracy of 
the assay requires extensive time–consuming washing steps. Nonetheless, this general 
approach has been used to assay FabH from various pathogenic microorganisms such as 
E. coli, E. faecalis, H. influenzae, S. pyogenes and S. aureus.58,59 Unfortunately, this 
method can’t be used to assay mtFabH because the long chain acyl-CoA substrates 
utilized by mtFabH have poor water solubility and are not readily resolved from the β-
ketoacyl-ACP product by the acid precipitation and extensive washing steps. Other assay 
formats such as a Scintillation Proximity Assay (SPA)27 and a filter disk assay26 have 
been described and can successfully be used for mtFabH. However, these assays involve 
either tedious preparation of a biotinylated malonyl-ACP substrate (SPA) or numerous 
washing steps (filter disk assay). The assay described here is a faster and more cost 
efficient for mtFabH, and eliminates the requirement of prior preparation of ACP 
substrates. Each individual step of the assay format is described in detail with special 
notes explaining the key steps. Furthermore, the advantages and disadvantages of this 
new assay method are discussed.  
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2.3 Experimental procedure: 
 2.3.1 Materials: 
The following reagents and conditions were used in the assay. The stock and working 
concentrations are indicated where required. 
1. Lauroyl-CoA or other long chain acyl-CoA (Sigma) – the stock solution of 100mM or 
10 mM were made in aqueous hydrochloric acid, pH 3.5, then diluted to 100uM 
working concentrations, aliquoted into appropriate working volumes and stored at – 
80 oC. 
Note: As acyl-CoA substrates are known to be unstable at neutral and higher pH, the 
solutions were made in acidic pH (aqueous hydrochloric acid solutions at pH 3.5) and 
stored in aliquots at –80 oC in working volumes (avoiding the need to repeatedly thaw 
and refreeze the solutions and the associated increased degradation). 
2. Radioactive [2-14C] Malonyl-CoA (American Radiolabeled Chemicals Inc.)(Stock 
concentration 1.8 mM; specific activity, 55mCi/mmol) diluted approximately 7.2 
times in aqueous hydrochloric acid solution (pH 3.5); the resulting 250  µM solution 
was aliquoted into appropriate working volumes and stored at – 80 oC.  
Note: The purity of the commercially available radioactive malonyl-CoA is a very 
important factor in this particular assay. Radioactive malonyl-CoA is prepared by the 
reaction of monothiophenylmalonate [malonyl-2-14C] and coenzyme A and the [2-
14C] malonyl-CoA product is purified by column chromatography. The radioactive 
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reactant is relatively non-polar, and if present in the [2-14C] malonyl-CoA sample, can 
lead to a high background during the assay and a substantially reduced signal to noise 
ratio. The manufacturer’s technical data sheet states that under these conditions the 
rate of decomposition is approximately 2% over the first six months. 
3. The over-expression of mtFabH enzyme in E coli and its purification has been 
described previously.27  
4. Sodium borohydride, toluene and tetrahydrofuran (THF) were from Fisher Scientific. 
5. Double distilled (DD) water (Sigma) for preparing buffers and reagents.  
Note: Divalent cations like Mg2+, Mn2+ catalyze the decomposition of sodium 
borohydride (NaBH4) preventing effective reduction of the β-ketoacyl-CoA product.  
Thus distilled water free of divalent ions was used in both the working assay and the 
preparation of the reducing reagent solution.60 
6. Potassium chloride powder, dibasic potassium phosphate powder (required for 
making reducing reagent) was ordered from Sigma. 
7. Screw cap microcentrifuge tubes (VWR). 
Note: Sodium borohydride produces significant effervescence when mixed with 
aqueous solutions. There is thus a potential for loss of the radioactive material from 
the vial at this point. A screw cap micro centrifuge tube should be used and tightened 
carefully before shaking the sample.  
8. EcoScint A scintillation cocktail (National Diagnostics). 
9. High-Density Polyethylene (HDPE) Liquid Scintillation Vials (Wheaton Science). 
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2.3.2. Method: 
The reaction was carried out in 20 µl total volume. This low volume using a 
minimum of the commercial radioactive malonyl-CoA sample with an unchanged 
specific activity balanced a high signal to noise ratio with a low cost. A larger volume 
assay would either require additional radioactive malonyl-CoA (increased cost) or 
addition of unlabeled malonyl-CoA (decreasing the specific activity and signal to noise 
ratio).  The concentrations of various components in a typical assay are shown in table 2. 
These volumes permitted determination of an IC50 value for a mtFabH inhibitor, but can 
be modified to perform routine enzymatic studies by replacement with an additional 2 µl 
of buffer. 
  
Component Stock Conc. Volume used Final conc./ amount 
Lauroyl-CoA 100 µM 2.5 µl 12.5 µM 
Malonyl-CoA 250 µM 1 µl 12.5 µM 
Inhibitor  10 X 2 µl 1 X 
mtFabH  2 µl 0.2 µg 
Sodium phos., pH 7.0 100 mM 12.5 µl 72 mM 
    
Total volume  20 µl  
 
 
Steps: 
1. The desired number of lauroyl-CoA, malonyl-CoA and mtFabH aliquots were thawed 
and kept at 4 0C.  
2. In a screw cap microcentrifuge tube, 2.5 µl of 100 µM lauroyl-CoA solution (final 
concentration 12.5 µM lauroyl-CoA), 1 µl of the 250 µM  [2-14C] malonyl-CoA 
Table 2: List of various components of a typical mtFabH assay. 
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solution (approx. 31,000 counts, final concentration 12.5 µM) and 2 µl of 10X 
inhibitor concentration (for inhibitor IC50 studies) were added. Then 0.1M sodium 
phosphate buffer, pH 7.0 was added to make up the volume to 18 µl.   
Note: The solvents used to deliver inhibitors have a predictable inhibitory effect on 
the activity of mtFabH.  The effect of various concentrations of dimethylsulfoxide 
(DMSO) and methanol (MeOH) is shown in figure 14. These figures indicate that the 
concentrations of solvent should ideally be at or below 1 % in the final assay volume. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Effect of solvent concentrations (DMSO and methanol) on mtFabH activity. 
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3. The reaction was initiated by addition of 2 µl of mtFabH 0.2 – 0.4 µg) solution in 0.1 
M sodium phosphate buffer, pH 7.0. Cap the microcentrifuge tube and kept at 37 0C 
for a designated time (typically 30-90 minutes). Under these assay conditions a linear 
reaction rate was observed for over a 2-hour assay period. (Figure 15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. The reducing reagent was generated by adding 5 mg of NaBH4 to 1 ml of a 70% 100 
mM K2HPO4, 100mM KCl, 30% THF solution. This solution was prepared fresh, and 
kept on ice until used. 
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Figure 15: Linearity of mtFabH activity with time. Enzyme is incubated with substrates at 37 oC 
for the specified time and product formation quantitiated as described above.   
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Note: The reducing solution consisted of 100 mM K2HPO4, 100mM KCl, 30% THF 
with sodium borohydride as the reducing agent. THF decreases the time required to 
quantitatively reduce the acyl thioesters (from 2 h to 10 min).60  The buffer can be 
stored at room temperature and NaBH4 should be added just before use. This 
reduction solution can be used for up to 2 hr if kept on ice, but potentially can lead to 
a loss of consistency in the assay results.   
5. A 0.5 ml of this reducing solution was added to the assay mixture; the vials were 
capped and shaken vigorously. Incubate the mixture at 37 0C degree for 15 minutes. 
Note: Reduction of long chain acyl-CoA is quantitative within 10 min. If inconsistent 
results are obtained the reduction reaction can be carried out for a longer time. 
6. Then 500 µl toluene was added to the mixture, the solution was mixed vigorously and 
then allowed to separate at room temperature. 
7. 320 µl of the upper phase (toluene) solvent was removed and combined with 
approximately 3 ml of a toluene or xylene based scintillation liquid  
8. The radioactivity of the toluene extract was determined with a Scintillation Counter 
and the actual radioactivity in non-aqueous phase was calculated by doubling the 
observed radioactivity.  
Note: The volume of toluene solution increases to about 640 µl due to partitioning of 
THF into toluene.  
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Figure 16: Schematic of mtFabH assay. The principle of separation of radioactive substrate and 
product is described in section 1.2. Radioactive center is shown by asterisk *. R’ can be either CoA or 
ACP. 
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2.4 Results and Discussion:   
The commonly used assays for FabH enzymes (TCA precipitation and other assay 
formats) are very time consuming and tedious to perform. The radioactive long chain acyl 
substrate processed by mtFabH is very difficult to separate from the radioactive product 
by the conventional washing step used in these assays. Recently, Brown et al57 have 
developed an alternative assay method for mtFabH based on an assay used originally by 
Garwin et al 61 for related FabF/FabB enzymes. This assay (Figure 16) involves the 
reduction of the assay mixture after reaction completion to produce radioactive substrate 
and product derivatives, which differ from each other in polarity. This difference permits 
simple separation of the two and quantitation of the radioactive product. The assay uses 
FabD to produce radioactive 2-14C malonyl-ACP in-situ from holo-ACP and malonyl-
CoA. The mtFabH catalyzes a decarboxylative condensation of this malonyl-ACP with 
the long chain acyl-CoA substrate ranging from hexanoyl CoA to arachidonyl CoA (C6 – 
C20), (see Table 3) to form a long chain β-ketoacyl-ACP. Reduction of this product by 
NaBH4 gives the corresponding radioactive long chain alkyl-1, 3-diol product with a 14C 
label at C2.  This product derivative can be partitioned into non-aqueous phase whereas 
the radioactive propane-1, 3-diol obtained by reduction of the radioactive malonyl 
thioesters stays in an aqueous phase. We have further simplified this by using malonyl-
CoA directly as a substrate, instead of malonyl-ACP (see figure 16). 
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A slower reaction rate for mtFabH is observed when malonyl-CoA was used in 
place of a malonyl-ACP substrate (Table 3). Dodecanoyl CoA is the preferred substrate 
for assays using either malonyl-CoA or ec malonyl-ACP (generated from the Escherichia 
coli ACP). With this acyl-CoA substrate the reaction rate is found to be about 4-fold 
slower with malonyl-CoA than with ec-malonyl-ACP or malonyl-ACPM (generated from 
the M. tuberculosis ACP). Catalysis with longer chain acyl-CoA substrates by the 
mtFabH is markedly reduced using either ec-malonyl-ACP or malonyl-CoA, but not 
malonyl-ACPM. One advantage of this modified assay is that all the substrates are 
commercially available. There is no need to obtain a purified ACP, or convert it to either 
the corresponding malonyl-ACP or biotinylated-malonyl-ACP, leading to significant 
savings in both time and cost. The direct utilization of radioactive malonyl-CoA in the 
        mtFabH Specific Activity ( nMoles/min/mg) 
Acyl-CoA primer chain length ec-Malonyl-ACP (*) mt-Malonyl-ACP (*) Malonyl-CoA (#) 
C6 0.39+/-0.07 1.74+/- 0.28 0.38+/- 0.064 
C8 5.98+/- 0.19 5.49+/-0.93 0.69+/- 0.18 
C10 6.34+/- 0.49 6.16+/- 0.24 0.758+/- 0.095 
C12 8.01+/- 1.07 7.24+/- 0.18 1.77+/-0.041 
C14 2.24+/-0.10 9.46+/- 0.41 0.3528+/- 0.0269 
C16 1.33+/- 0.10 9.27+/- 0.56 0.128+/- 0.086 
C18 0.60+/- 0.10 10.39+/- 0.51 0.036+/- 0.0009 
C20 0.06+/- 0.02 9.02+/- 0.27 0.155+/- 0.0133 
Table 3: Effect of ACP on acyl group specificity of mtFabH. Total condensation activity of mtFabH is 
determined using ec-malonyl-ACP, mt-malonyl-ACP or malonyl-CoA and a range of different acyl-CoA 
substrates. (* - Data adopted from reference 57, # - data for the assay described herein). 
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assay also maximizes the use of this substrate for the assay, avoiding the inevitable losses 
associated with conversion to malonyl-ACP. The assay also uses lower concentrations of 
malonyl-CoA (12.5 µM versus the 50 µM) typically used in other formats, both 
decreasing the amount of material and potentially increasing the range of the assay to 
include both poor and good competitive inhibitors.  A final advantage of this new assay 
format is an excellent 60:1 signal to noise ratio (the scintillation proximity assay27 is 
approximately 10:1).  
 
2.5 Conclusion: 
In conclusion, the assay described herein is a much faster and less cumbersome 
way to screen the potential inhibitors of mtFabH enzyme. Furthermore, the assay doesn’t 
use ACP and thus can serve as an “ACP independent assay” for mtFabH enzyme. This 
particular aspect can be utilized to investigate the role of various types of ACP substrates 
for example- cognate vs non-cognate ACP. This assay is used to evaluate a series of 
novel mtFabH inhibitors in later chapter (6) of this dissertation. 
 
 
 
 
 
 
 
   
  
40 
 
 
 
3. Crystal structure of a substrate complex of Mycobacterium 
tuberculosis β-Ketoacyl-Acyl Carrier Synthase III (mtFabH) with 
Lauroyl-Coenzyme A 
 
3.1 Summary 
β-ketoacyl-acyl carrier protein synthase III (FabH) catalyzes a two step reaction 
that initiates the pathway of fatty acid biosynthesis in plants and bacteria. In 
Mycobacterium tuberculosis, FabH catalyzes extension of lauroyl, myristoyl and 
palmitoyl groups from which cell wall mycolic acids of the bacterium are formed. The 
first step of the reaction is an acyl group transfer from acyl-coenzyme A to the active-site 
cysteine of the enzyme; the second step is acyl chain extension by two carbon atoms 
through Claisen condensation with malonyl-acyl carrier protein. The crystal structure of a 
type II dissociated M. tuberculosis FabH, which catalyzes extension of lauroyl, myristoyl 
and palmitoyl groups, has been determined before. In this study, we describe the first 
long-chain Michaelis substrate complex of a FabH, that of lauroyl-coenzyme A with a 
catalytically disabled Cys→Ala mutant of M. tuberculosis FabH. An elongated channel 
extending from the mutated active-site cysteine defines the acyl group binding locus that 
confers unique acyl substrate specificity on M. tuberculosis FabH. CoA lies in a second 
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channel, bound primarily through interactions of its nucleotide group at the enzyme 
surface. The apparent weak association of CoA in this complex may play a role in the 
binding and dissociation of long chain acyl-CoA substrates and products and poses 
questions pertinent to the mechanism of this enzyme. 
 
3.2 Introduction 
The crystal structure of the homodimeric type II mtFabH was found to be very 
similar in conformation to the other determined FabH structures,62,63 which adopt the 
thiolase fold. The thiolase fold defines a growing family of enzymes that includes yeast 
peroxisomal 3-ketoacyl-CoA thiolase,64 β-ketoacyl-acyl carrier protein synthases I 
(FabB)65 and II (FabF),66,67 two plant type III polyketide synthases68,69 and one FabH 
homologue from a type II bacterial polyketide synthase gene cluster.70 In contrast to the 
Escherichia coli FabH structures, the mtFabH structure has a long channel extending 
from its active-site Cys112, which has been tentatively identified as a long-chain acyl 
group binding channel. This channel could accommodate an acyl chain of 12–16 carbon 
atoms, consistent with the specificity of mtFabH observed in solution reactions.26,27 A 
second channel, also extending from the active-site cysteine, corresponds to the CoA 
binding channel identified in the E. coli FabH crystal structures. However, in the 
unliganded mtFabH crystal structure, this second channel was occupied by electron 
density that could be accurately modeled as a lauric acid, whose presence we ascribed to 
adventitious binding during expression and purification of the recombinant mtFabH.  
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To test our identification of these putative substrate binding channels and to 
determine the binding mode of the physiologically relevant longer chain acyl-CoA to 
mtFabH, we have determined the crystal structure of a substrate complex of lauroyl-CoA 
with a catalytically inactive C112A mutant of this FabH. This complex represents the 
presumed Michaelis complex of the reaction, which precedes acylation of the active-site 
Cys112 and release of the CoA cofactor. Replacement of the active-site Cys112 of FabH 
by alanine removes the enzyme acyl acceptor residue, thereby preventing the initial 
transacylation and capturing the Michaelis complex.  
 
3.3 Experimental Procedures 
3.3.1 Materials 
All general chemical supplies not listed below were ordered from standard 
companies and were reagent grade or better. The source of specific supplies were as 
follows: BL21DE codon plus cells and pET-15b plasmid for cloning were bought from 
Novagen, QuikchangeTM XL site-directed mutagenesis kit was from Stratagene, HiTrap 
TM
 Chelating and Desalting columns used for protein procedures were from GE 
Biosciences (formerly Amersham Biosciences), 50 kDa cutoff Microcon and Centricon 
filters used were from Fisher scientific, crystal screen kits 1 and 2 and other 
crystallization supplies were from Hampton research, primers were ordered from 
Integrated DNA Technology and the QiaPrep MiniprepTM kit for DNA extraction was 
from Qiagen.  
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3.3.2 Construction of mtFabH mutants 
The C112S and C112A mutations were made on the open reading frame Rv0533c 
(mtFabH), which was cloned into the expression vector pET-15b as described.27 Mutants 
were made according to the protocol provided for the Stratagene Quickchange XL site-
directed mutagenesis kit and primers designed to substitute serine and alanine for 
Cys112. Primers used for introducing point mutations were, for the C112S mutant: 
forward 5′-GAT CTT TCG GCG GGG AGC GCC GGA TTC GGA TAT G-3′, reverse 5′ 
-CAT ATC CGA ATC CGG CGC TCC CCG CCG AAA GAT C-3′, and for the C112A 
mutant: forward 5′-GAT CTT TCG GCG GGG GCC GCC GGA TTC GGA TAT G-3′ 
and reverse 5′-CAT ATC CGA ATC CGG CGG CCC CCG CCG AAA GAT C-3′. 
Mutations were confirmed by sequence analysis of the constructs. Plasmid was purified 
using the QIAprep miniprep kit following the protocol available with the kit.  
 
3.3.3 Enzyme expression and purification 
Competent E. coli BL21DE3 Codon Plus cells were transformed with pET-15b 
carrying either the C112S or C112A mutant FabH insert. Transformants were grown in 
LB medium to an absorbance of 0.4–0.6, induced with 0.1 mM isopropyl-β-d-
thiogalactopyranoside, and incubated for an additional four hours at 37 °C. Cells were 
harvested by centrifugation at 10,000 g for ten minutes at 4 °C and stored at −20 °C 
overnight. After lysis with lysozyme on ice for 30 minutes, cells were sonicated on ice 
and then centrifuged at 12,000 g for 30 minutes at 4 °C. The supernatant was loaded onto 
a Hitrap chelating 5 ml column and washed with a gradient step from 0 mM to 120 mM 
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imidazole in 50 mM sodium phosphate buffer (pH 8.0) with 300 mM sodium chloride. 
FabH was eluted with 1 M imidazole under the same buffer conditions. The high 
concentration of imidazole employed in the washing step improves the homogeneity of 
the mtFabH band as assessed by SDS-PAGE analysis. The mtFabH was desalted in 100 
mM sodium phosphate buffer (pH 7.0), and kept at 4 °C overnight. Protein was 
concentrated in centricon tubes and assayed by Bradford assay using BSA as standard. 
For crystallization, the concentration of mtFabH used was in the range of 4–15 mg/ml.  
 
3.3.4 Crystallization, data collection and structure determination 
Note: This part of the project was kindly performed by Dr. Faik Musayev, Dr. Tonie H. Wright and Dr. J. 
Neel Scarsdale. 
 
Crystallization conditions were initially screened at room temperature using the 
Hampton crystal screen kits and the hanging drop method. Small crystals of apo-mtFabH 
(C112A) were obtained with a number of precipitants, and further refinement of 
conditions gave promising diffracting crystals from ammonium formate and sodium 
chloride as precipitants. Optimal crystals were obtained from drops made from 3 µl of 
protein solution at 4 mg/ml in 100 mM sodium phosphate buffer (pH 7.5) to which was 
added 3 µl of reservoir solution consisting of 2 M NaCl and 100 mM sodium Mes buffer 
(pH 6.5). Crystals were cryoprotected in solutions containing 100 mM sodium Mes buffer 
(pH 6.5), 2 M NaCl and 28% glycerol, the final concentration of glycerol being reached 
in two steps of 45 seconds each before flash cooling in the liquid nitrogen stream. 
Crystals diffracted to a resolution limit of 1.85 Å on a Rigaku rotating anode X-ray 
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source run at 50 kV, 100 mA equipped with Osmic confocal optics. A total of 110 frames 
of 1.3° oscillations were measured using an RAxisII image plate detector. Oscillation 
data were integrated with MOSFLM and merged with SCALA. Data collection statistics 
are summarized in Table 4.  
The complex of mtFabH (C112A) with lauroyl-CoA was prepared by mixing a 
mtFabH solution with 50 mM lauroyl-CoA in doubly distilled H2O. The best crystals of 
the C112A–lauroyl-CoA complex were obtained from 1.6 M ammonium formate in 100 
mM sodium Hepes buffer (pH 6.5). The plate form crystals reached maximum size of 
about 0.05 mm×0.1 mm×0.15 mm in two to three days. To minimize the effect of 
hydrolysis during crystallization, data were collected on crystals as soon as they reached 
sufficient size. Crystals were cryoprotected for a few seconds in a solution containing 2.7 
M ammonium formate, 0.4 mM lauroyl-CoA, 14% glycerol, 100 mM sodium Hepes (pH 
6.5), followed by quick transfer to a similar solution containing 3.5 M ammonium 
formate and 28% glycerol and freezing at 100 °K in the nitrogen stream. The crystals 
diffracted beyond 2.3 Å resolution and data sets of 135 oscillation frames were collected 
with a step size of 2.5°. Oscilllation data were integrated and merged with BIOTEX.  
A model consisting of the biological dimer from our structure of mtFabH (RCSB 
entry 1HZP)27 was used as a search model for molecular replacement for both the 
liganded and unliganded data sets. A cross-rotation search was carried out using the fast 
direct search protocol as implemented in CNS version 1.0.71 For the unliganded data set, 
solutions corresponding to the highest peaks from the cross-rotation search were used as 
input to a translation search as implemented in CNS version 1.0. Inspection of initial  
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Table 4: Data collection and refinement statistics for mtFabH C112A and C112A.lauroyl-CoA 
(C112A/LCOA) structures 
 C112A C112A●LCOA 
Data Collection 
Space Group P212121 P1 
Unit Cell 55.25,109.01,110.98, 
90.,90.,90. 
55.57,63.19,55.33,1
13.2,100.8,92.7 
Resolution (Å) 1.85 2.3 
Rmerge1 overall/highest resolution shell 0.044/0.14 0.073/0.26 
<I>/<F(I)> overall/highest resolution shell 9.1/5.0 8.7/1.9 
Completeness overall/highest resolution shell 0.98/0.98 0.92/0.90 
Nobs  56576 28398 
Multipliciity 4.6 2.9 
Wilson Plot B (Å2) 26.7 46.6 
Optical Resolution (Å)2 1.44 1.77 
   
Refinement 
Rwork3  overall/highest resolution shell 0.186/0.219 0.206/0.333 
Rfreec overall/highest resolution shell 0.208/0.247 0.247/0.412 
Completeness, overall/highest resolution 
shellc 
0.975/0.809 0.950/0.757 
<B>(Å2) 13.2 37.3 
Nwork 50770 26967 
Nfree 5143 1431 
Natoms 5391 5203 
Ndegrees of freedom Torsion Angle Dynamics 2277 2321 
Rmsd from ideal: 
          bond length (Å) 
 
0.007 
 
0.008 
          bond angles (o)                                                               1.085 1.323 
Ramachandran Plot 
Most favored(%) 
Additionally Allowed(%) 
Generously Allowed(%) 
Forbidden(%) 
 
90.4 
  8.9 
  0.4 
  0.4 
 
89.5 
 9.8 
 0.7 
 0.0 
Cruickshank’s Diffraction Precision 
Indicator4 
0.167 0.493 
Estimated Maximal Coordinate Error 0.059 0.218 
                                                          
1
 Rmerge = ΣΣi Ih-Ihi / ΣΣi Ih where Ih is the mean intensity of reflection h.  All data with 
I>-3F  are included. 
2
 W = (F2Patterson + F2sph)1/2  the expected minimum distance between two resolved atom 
peaks  
3
 Calculated with all reflections  
4
 σ(x) = (Natoms/Nobs)1/2c–1/3dminRfree 
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2mFo−dFc maps generated with phases from the molecular replacement solutions 
indicated the presence of broken density in the putative acyl and pantetheinate channels 
of both monomers consistent with the binding of lauroyl-CoA in the C112A-lauroyl-CoA 
crystal. No significant density was observed in maps generated for the unliganded crystal.  
Models were refined iteratively using simulated annealing and torsion angle dynamics as 
implemented in CNS version 1.0 coupled with TLS71 and positional refinement in 
REFMAC572 followed by manual rebuilding into 2mFo−dFc, mFo−dFc and 2mFo−dFc 
composite omit maps using the programs O,73 TOM or Xfit.74 In the final stages of 
refinement, 556 and 197 water molecules were added to the unliganded and liganded 
structures, respectively, on the basis of the presence of peaks with heights >3σ in the 
mFo−dFc maps. During iterative rebuilding, residue geometries were monitored via 
PROCHECK, WHATCHECK75 and OOPS2,76 while van der Waals contacts and 
hydrogen bonds were monitored using PROBE77 as integrated with Xfit. Model 
coordinate errors were estimated using Cruikshank's diffraction precision indicator as 
implemented in SFCHECK.78 
 
Accession Numbers: 
Coordinates for the mtFabH C112A mutant and C112A + lauroyl-CoA have been 
deposited in the Protein Data Bank (accession codes 1U6E and 1U6S) 
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3.4 Results 
3.4.1 Electron density interpretation 
To obtain a stable complex of lauroyl-CoA with mtFabH, we made both C112A 
and C112S mutants to suppress transacylation activity to the active-site cysteine. 
Complexes of lauroyl-CoA with both the C112A and C112S mutants were made in 
solution and crystallized under significantly different conditions in similar but non-
identical lattices. Both electron density maps showed density in the CoA channel and in 
the putative acyl-binding channel of each subunit of the homodimer, but the density for 
the C112S mutant was weaker than that for C112A. Only the structure of the C112A 
ligand complex is described and discussed here. The structure of the unliganded mtFabH 
(C112A), whose conditions of crystallization and lattice type are completely different 
from those of the wild-type, is essentially identical with that of the wild-type mtFabH 
previously described with one minor exception. The higher resolution of this structure 
revealed a bend in helix Cα1 (for nomenclature, see Davies et al.62) between residues 218 
and 221 not reported earlier.27 This bend is not present in the corresponding helix of E. 
coli FabH and may be a consequence of lattice interactions in the mtFabH (C112A) 
structure (see next section). Crystal parameters and statistics for data collection and 
refinement of the unliganded and liganded crystal forms of mtFabH (C112A) are shown 
in Table 4.  
Electron density for the lauroyl-CoA ligand in complex with C112A mtFabH was 
readily fit to each subunit of the homodimer in the omit and 2Fo−DFc maps. Electron 
density for the adenosine-3′-phosphate moiety of CoA is almost complete in the A 
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subunit, but is broken in several places in the composite omit map of the corresponding 
site of the B subunit. There is a break in electron density at the pyrophosphate-ribose 
linkage of the CoA in both subunits (Figure 17). The descriptions that follow pertain to 
the model for lauroyl-CoA in the A subunit binding site, but those of the B subunit are 
very similar. There are no significant differences in conformation between the two 
subunits of the biologically functional homodimer of either the unliganded or complexed 
mtFabH, as was also observed for complexes of E. coli KAS I covalently66 bound to C10 
and C12 acyl groups and E. coli FabH64 with bound CoA.  
Figure 17: Composite omit map electron density for lauroyl-CoA bound to subunit A of mtFabH 
homo-dimer.  
 
   
  
50 
3.4.2 Packing of FabH dimers in the crystal lattice 
The tight functional FabH homodimers are related to each other in the triclinic 
lattice by a pseudo-dyad axis parallel with the dyad of the functional homodimer (Figure 
18 (a)). Although much smaller in area than the contact surface between the monomers of 
the biological homodimer, the contact area between non-crystallographic dimers is not 
negligible (1535 Å2). It is formed across a local dyad by pairwise interactions between 
helix Cα1 of one monomer (residues 210–231) and helix Cα2 (residues 248–259) and 
part of helix L1α2 (28–35) of an adjacent monomer. A consequence of this interaction is 
that the 3′-phosphoryl-adenosine pyrophosphate groups of CoA in monomer subunits of 
different functional dimers are in close proximity across this local pseudo-dyad (Figure 
18 (b)). The CoA adenosine nucleotide group of subunit A lies immediately next to this 
pseudo-dyad, which appears to force a displacement of the corresponding part of the 
ligand in the opposing B subunit. We infer that the local static disorder in the 3′-
phosphoadenosine pyrophosphate groups of the CoA in each monomer is a consequence 
of this close approach of polyanionic groups.  
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Figure 18: (a) Model of the mtFabH dimer with lauroyl-CoA (ball and stick models: blue in subunit A 
and magenta in subunit B). Arrow 1 denotes the non-crystallographic 2-fold rotation axis relating the 
monomers of the functional dimer; arrow 2 denotes a distinct pseudo-2-fold rotation axis relating the 
functional dimers. (b) Contact region of two functional homodimers of the asymmetric unit: The 
proximity of adenosine triphosphate groups of lauroyl-CoA is depicted at the non-crystallographic 2-fold 
rotation axis (2) displayed in (a).  
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3.4.3 The lauroyl binding channel 
Electron density for the lauroyl group in the mtFabH–lauroyl-CoA structure is 
clear and shows this chain lying in the channel hypothesized from the unliganded 
mtFabH structure (Figure 17). The lauroyl chain is extended, but with a bend at C7–C8 
which lies between Thr (B87) and Thr (A145). A similar bend at C6 was observed in 
structures of decanoyl and dodecanoyl groups in complex with KASI and was attributed 
to the presence of Phe201 in the acyl channel.66 As noted earlier,27 Thr87 plays a 
permissive role in opening this channel to longer acyl chains, in contrast to E. coli FabH, 
in which residue 87 is a phenylalanine, which restricts the acyl chain length to four 
carbon atoms or less. There is sufficient room at the distal end of the lauroyl chain to 
accommodate four more carbon atoms, consistent with the observed in vitro activity of 
mtFabH toward myristoyl- and palmitoyl-CoA substrates, as well as lauroyl-CoA.26 The 
acyl carbon of the lauroyl group is juxtaposed at a distance of 2.20 Å to the modeled 
Cys112 Sγ of wild-type mtFabH overlaid on the Ala112 mutant structure, and the 
carbonyl oxygen makes hydrogen bonds of unequal length (3.01 Å and 2.66 Å) to the 
main-chain –NH– of A112 and A306 (Figure 19). This oxyanion hole is a conserved 
feature of the ketoacyl synthases and stabilizes the inferred tetrahedral intermediate.  
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3.4.4 Conformation and interactions of coenzyme A 
The CoA part of lauroyl-CoA lies in the channel in which a putative lauric acid 
binds to the unliganded wild-type mtFabH structure. Although this density is contiguous, 
except at the pyrophosphate linkage, and has structural features through most of its 
length, it is not sufficiently well resolved to be unambiguously fit by the CoA model. The 
model of the CoA from the ecFabH complexes cannot be fit throughout to the electron 
Figure 19: Model centered on the lauroyl acyl group linkage to CoA in subunit A showing the mutant 
active-site alanine overlaid on the wild-type active-site cysteine A112(C)). Dotted lines are hydrogen bonds 
from proton donors of the oxyanion hole to oxygen of the acyl group. 
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density of the mtFabH–CoA structure: the mercaptoethylamine and nucleotide 
pyrophosphate portions of the CoA in the mtFabH–lauroyl-CoA complex differ 
significantly in position and conformation from those observed in the ecFabH–CoA 
complexes, while the pantetheinate parts appear to be more similar (Figure 20).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Stereo view of amino acid residues in proximity to the bound CoA portion of lauroyl-
CoA in the A subunit of mtFabH (a) and of CoA bound to E. coli FabH (b).  
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Most of the interactions of CoA with mtFabH occur at the distal adenosine 
nucleotide terminus, which lies at the mouth of the CoA binding channel. The adenine 
ring of CoA is sandwiched between the planes of Trp32 and the guanidinium group of 
Arg151, as was observed for the ecFabH–CoA complex,63 and the adenine amino group 
makes a hydrogen bond to Oγ of Ser28. This intercalation of the adenine ring requires 
unstacking of the Trp32 and Arg151 side-chains of the unliganded FabH structure on 
binding of the cofactor ligand. The 3′ phosphoryl groups of the CoA in the A subunit 
interact with Arg151 from the A subunit and also from a lattice-related B subunit across 
the non-crystallographic-dyad axis (2) described above. Density for the ribose 
pyrophosphate of the CoA in the mtFabH–lauroyl-CoA complex is broken at the 
pyrophosphate, but it is clear that the model of CoA derived from the ecFabH–CoA 
complexes cannot be fit to it. This is likely due to the close crystal lattice contacts across 
the non-crystallographic dyad described above in the mtFabH–lauroyl-CoA complex. 
This dyad lies between the 3′-ribose phosphate groups of CoA in different dimers in the 
lattice and the juxtaposition of these two anionic groups appears to induce static disorder 
at this site. The high temperature factors for the CoA in the mtFabH complex indicate 
some disorder in the cofactor and are consistent with the paucity of interactions between 
the cofactor and the protein. The temperature factors for protein groups lining this 
channel are near the mean for the overall structure, further confirming that the disorder is 
confined to the cofactor. The temperature factors for the CoA moiety in the channel are 
not an artifact of erroneous occupancies, since the temperature factors for the lauroyl 
group are much lower than those of the CoA. In the structure of the ecFabH–CoA 
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complexes, the temperature factors for those parts of the cofactor visible in the electron 
density map are only slightly higher than those for the protein. These observations are 
consistent with a loosely bound CoA in the mtFabH–lauroyl-CoA complex. The possible 
origins and implications of this are discussed below. 
 
3.5 Discussion  
As a regulated catalyst of the first step in an essential biosynthetic pathway, FabH 
has been identified as a potential target for development of new antibacterial agents. The 
distinctions between the monomeric type I FAS of animals and the type II dissociated 
FAS of bacteria offer the prospect that a target-specific antibiotic would discriminate 
between host and pathogen. The crystal structure described here is the first of an intact 
substrate complex of FabH with an acyl-CoA, and provides a template for the design of 
possible inhibitors of this vulnerable class of enzymes.  
Previous attempts to determine the structure of complexes of ecFabH with acyl-
CoA (acetyl and malonyl) prepared by incubation either failed to show electron density 
for the acyl group or were transacylated.63 Electron density was visible, however, for the 
CoA ligand in these structures and it provided information on the mode of cofactor 
binding in the product complex. Crystal structures for two acetyl–CoA complexes with 
ecFabH (1HNH, 1HND) have been determined. In one, the acetyl group is covalently 
bound to the active-site cysteine Sγ, but is missing in the other, though the CoA is 
retained in the binding channel of both. In the malonyl–CoA complex with ecFabH 
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(1HNJ), the malonyl group is not observed and was inferred to be disordered or to have 
hydrolyzed during preparation, but CoA is observed in the binding channel. The acetyl–
CoA complex with ecFabH is therefore a product complex of the initial transacylation 
step of the reaction, probably stabilized by the retention of bound CoA, which prevents 
ingress of water that would hydrolyze the thioester linkage. The other two ecFabH 
complexes, while not on the reaction pathway, confirm the observed conformation of the 
CoA as that for product complex, except for variation in the tail from C7 of the 
pantetheinate through the mercaptoethylamine group.  
In contrast to ecFabH–CoA complexes, formation of CoA crystal complexes with 
mtFabH, either by soaking or cocrystallization, has been problematic. When lauroyl–CoA 
is used as substrate to try to prepare substrate or product complex with wild-type 
mtFabH, only lauric acid is observed to bind in the acyl channel. This latter result 
suggests that the lauroyl-thioester intermediate is hydrolyzed by water that can enter the 
active-site in the absence of bound CoA and is consistent with a low affinity of CoA for 
its binding channel in mtFabH relative to ecFabH. By utilizing a catalytically disabled 
FabH mutant, C112A, we have been able to visualize the intact lauroyl–CoA substrate 
bound to mtFabH. The acyl linkage between the lauroyl group and the β-
mercaptoethylamine of the CoA is clearly visible in our electron density map. The length 
of the acyl channel in the mtFabH–lauroyl-CoA complex is consistent with the substrate 
specificity of this enzyme in solution and confirms our hypothesis for the unique role of 
this type II FabH in the biogenesis of long chain fatty acids in M. tuberculosis.27 
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Of the few known structures64,69,70 and inferred models79 of CoA complexes with 
ketoacyl-synthases, the CoA of the mtFabH–lauroyl-CoA complex described here 
appears to be the least stabilized in its binding site. The observed difference in binding 
mode of CoA between the E. coli and mtFabH complex structures could arise from any of 
several sources: (i) differences in the residues that interact with the CoA in the two 
FabHs; (ii) effects of the CoA-linked lauroyl group; (iii) distinctions between substrate 
and product complexes; (iv) the influence of lattice interactions on the conformation of 
CoA. 
There are two amino acid differences between ecFabH and mtFabH in the 
pantetheinate binding part of the CoA channel: L189, which is Ile in mtFabH, and M207, 
which is Leu in mtFabH. HINT analysis80 of the ecFabH and mtFabH complexes with 
CoA shows that these two residues make unfavorable polar-hydrophobic interactions 
with the pantetheinate as built in the mtFabH complex. These two unfavorable contacts, 
plus several favorable ones in the ecFabH–CoA complex that are not made in the 
mtFabH–lauroyl-CoA complex are consistent with more stable binding of CoA in the 
ecFabH–CoA complex than in the mtFabH.  
It is possible that binding of the lauroyl group affects the conformation of the 
CoA in the mtFabH–lauroyl-CoA complex relative to that observed in the ecFabH–CoA 
complex. This seems unlikely for substrate acyl–CoA complexes, since the 
stereochemical requirements for acylation will be the same for small and large acyl 
groups. However, because we are comparing a substrate complex (mtFabH–lauroyl-CoA) 
with a product complex (ecFabH–CoA), differences in structure could be a consequence 
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of differences between these chemically distinct intermediates on the reaction pathway. 
The apparent higher stability of the CoA in the ecFabH complexes than in the mtFabH–
lauroyl-CoA complex may reflect differences in the energetics of binding substrate 
versus product. These differences are most likely to be manifested at the 
mercaptoethylamine part of the CoA where chemical bonding differs in the two 
complexes. This could explain the major differences in conformation of this part of the 
CoA between the ecFabH–CoA and mtFabH–lauroyl-CoA complexes. In this connection, 
we note that the overall conformation of the lauroyl–CoA ligand in the mtFabH complex 
differs from that of two other long-chain acyl–CoA complexes in the RCSB database 
(1H9G, 1IYK). This is consistent with a relatively flat energy surface for CoA conformers 
and a dominant role for the protein binding site in determining the conformation of bound 
CoA. 
Finally, the close lattice contacts involving the nucleotide ends of CoA in the 
mtFabH–lauroyl-CoA complex are likely to induce changes in conformation of the CoA 
in each copy of the complex. This is a probable cause for the difference in conformation 
of the ribose pyrophosphate group in the ecFabH–CoA complex versus that in the 
mtFabH–lauroyl-CoA complex. The electron density for this part of the CoA in the latter 
complex is broken, which is consistent with disorder imposed by the close contact of 
anionic groups. Nevertheless, density for the adenine ring is complete in subunit A and 
substantial though incomplete in subunit B, indicating that this interaction is a highly 
stabilizing one and can tolerate disorder in immediately contiguous groups.  
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The difference in apparent stability of bound CoA between the mtFabH–lauroyl-
CoA and the ecFabH–CoA complex may reflect compensating contributions of the acyl 
and CoA moieties that result in isoenergetic binding of both long and short acyl-CoA 
substrates. The longer acyl chain of mtFabH substrates will be more stable in its 
extended, sequestered hydrophobic binding channel than an acetyl group and could 
thereby anchor the CoA portion of the substrate, which may have lower stability bound to 
the mtFabH than to ecFabH. It may be more important to note that neither the ecFabH 
product complex nor the mtFabH substrate complex described here shows numerous or 
strong stabilizing interactions of bound CoA in the CoA channel. This may reflect a 
requirement for facile dissociation of the product CoA ligand after the initial 
transacylation step of the reaction and could help drive this reaction, which is a ground 
state exchange with little intrinsic energy difference between substrate and product. 
These arguments and the structure of the complex of lauroyl-CoA with mtFabH 
raise two questions relating to the trajectory and energetics of long chain acyl group 
binding to FabH. For instance, how does the long acyl chain enter the seemingly 
restricted binding channel in mtFabH. If the acyl group threads through the CoA channel 
past the active-site cysteine to reach the buried acyl channel, what drives that 
translocation? And how is a long chain ketoacyl-ACP product dissociated from the 
enzyme? In the case of long chain acyl-CoA binding, differential stability of the acyl 
group in its highly hydrophobic specificity pocket could promote its migration beyond 
the CoA channel, culminating in a substrate complex stabilized primarily by the 
sequestered acyl group and the nucleotide end of the CoA. An alternate mechanism 
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where the substrate entry is facilitated by conformational changes in the enzyme is also 
possible. Following transacylation to the active-site cysteine, the paucity of interactions 
of the CoA in the pantetheinate binding channel would permit its ready dissociation. This 
might be further assisted by disruption of the adenine nucleotide interaction of CoA at the 
mouth of the channel through competition with incoming malonyl-ACP. However, 
following decarboxylation and condensation by mtFabH, a long-chain ketoacyl-ACP 
product complex would be stabilized in its bound state due to the buried position of the 
acyl group in the hydrophobic channel. Dissociation of this long-chain ketoacyl-ACP 
product would seem to require facilitating mechanisms. 
 
3.6 Conclusions: 
The crystal structure of this complex confirms our identification of the acyl 
binding channel and shows the mode of binding of the acyl group in this channel and of 
CoA in the other channel. This supports the hypothesized function for this FabH as an 
initiator of mycolate biosynthesis utilizing acyl-CoA chains of length 12–16 carbon 
atoms. This structure also suggests distinctions from the ecFabH in its interactions with 
CoA and poses several important questions regarding the binding of substrates and 
energetics of the FabH reaction mechanism.  
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4.  Probing reactivity and substrate specificity of both subunits of the 
dimeric Mycobacterium tuberculosis FabH (mtFabH) using alkyl-CoA 
disulfide inhibitors and acyl-CoA substrates 
 
4.1 Summary 
The dimeric Mycobacterium tuberculosis FabH (mtFabH) catalyses a Claisen-
type condensation between an acyl-CoA and malonyl-Acyl Carrier Protein (ACP) to 
initiate the Type II Fatty Acid Synthase cycle. To analyze the initial acylation of mtFabH 
with acyl-CoA, we challenged it with a mixture of C6-C20 -CoAs and the ESI-MS analysis 
showed reaction at both subunits and 'a strict specificity for C12-CoA. Crystallographic 
and ESI-MS studies of mtFabH with decyl-CoA disulfide inhibitor revealed the decyl 
chain bound in acyl-binding channels of both subunits through disulfide linkages to the 
active site cysteines. These data provide the first unequivocal evidence that both subunits 
of mtFabH can react with substrate or inhibitor. The discrepancy between the observed 
C12-CoA substrate specificity in the initial acylation step and the higher catalytic 
efficiency of mtFabH for C18-C20 -CoA substrates in the overall mtFabH catalyzed 
reaction suggests a role for M. tuberculosis ACP as a specificity determinant in this 
reaction.    
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4.2 Introduction: 
Enzymological studies have shown that mtFabH can utilize a wide range of C12-
C20 acyl-CoA substrates,26,27,57 which distinguishes it from FabH in other type II FAS 
systems that typically utilize C2-C6 acyl-CoA substrates.26,81 Initial studies using 
malonyl-E. coli ACP (ecACP) as the malonyl-ACP substrate of mtFabH indicated a 
broad C8-C20 acyl-CoA substrate specificity.26 The C10-C12 acyl-CoA substrates were 
processed most efficiently (6-8 nmol/min/mg), while the reaction rates using the putative, 
physiological longer chain (C18-C20) acyl-CoA substrates were significantly lower (<0.6 
nmol/min/mg).57 This same pattern has recently been observed in assays using malonyl-
CoA in place of malonyl-ACP [data in publication]. However, mtFabH has a higher 
turnover number toward longer chain C14-C20 acyl-CoA substrates (9-10.5 nmol/min/mg) 
in the overall reaction when cognate ACPM is used in the assay.57 The basis for this 
differential efficiency in processing longer chain acyl-CoA substrates remains unclear.   
The crystal structures of mtFabH and an array of mutants have raised other 
questions relating to processing of longer chain C18-C20 acyl-CoA substrates. (see chapter 
3 and ref. 27,57) mtFabH has a closely similar topology and active site architecture to that 
of E. coli FabH (ecFabH).  However, whereas ecFabH has a small acyl binding pocket 
contiguous with the pantetheinate binding channel, the substrate binding pocket of 
mtFabH is L-shaped, consisting of a solvent accessible pantetheinate binding channel 
connected to a closed, elongated acyl binding channel. The active site catalytic triad 
(Cys112-His244-Asn274) lies at the junction of the two arms of the “L”.  The closed 
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distal end of the acyl binding channel imposes an upper length limit of C16 for acyl-CoA 
substrates in the static mtFabH structure. An mtFabH crystal structure of the Michaelis 
complex of dodecanoyl-CoA with an inactive C112A mutant (chapter 3) clearly shows 
substrate bound in the “L” shaped channel of each monomer, with the dodecanoyl group 
in the acyl binding channel. The length of this channel raises the as yet unanswered 
question of how longer C18-C20 acyl-CoA substrates bind and acylate mtFabH.   
Previous observations made with both the ecFabH and mtFabH raise a third 
question of whether both monomers of the mtFabH homodimer are acylated. In the case 
of the ecFabH crystal structures,63,82 including an unliganded tetragonal form of ecFabH 
in which several polypeptide segments that contribute to the structure of the substrate 
binding site and to the dimer interface are disordered, indicate structural equivalence of 
the two monomers. However, we have recently obtained a crystal structure of the 
inhibition complex of ecFabH with a methyl-CoA disulfide (MeSSCoA) in which there is 
a methyl disulfide linkage to the active site cysteine in only one monomer of the dimer.83 
Attempts to obtain a crystal structure in which both subunits are modified have thus far 
been unsuccessful. Kinetic analysis of MeSSCoA inhibition suggests that both subunits 
of ecFabH are modified via a biphasic process in which one subunit is modified quickly 
and the second more slowly. A similar biphasic acylation of the ecFabH with acetyl-CoA 
substrate was also observed.  These observations have led to the proposal that ecFabH 
exists in an open form that orders around either a substrate or inhibitor in one subunit, 
and in so doing retards binding of ligand to the second subunit.83 Similar asymmetry of 
ligand binding and disorder→order transitions may occur in mtFabH and may severely 
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hamper ligand binding and reaction at the second subunit. Indeed, it has been reported 
that acylation studies carried out using the mtFabH and radiolabeled decanoyl-CoA (in a 
molar ratio of 1:2.3) result in only 23% acylation of the protein57.  Our complex of the 
mtFabH C112A mutant with lauroyl-CoA indicates structural identity of the two 
monomers (as seen for all mtFabH structures) and also that under prolonged incubation 
dodecanoyl CoA can bind in both subunits of the enzyme (chapter 5)     
In this work we have addressed these questions of mtFabH specificity and 
mechanism using ESI-MS and crystallography to monitor the reaction of the wild type 
mtFabH with both a decyl-CoA disulfide inhibitor and a wide range of C6-C20 acyl-CoA 
substrates. We have shown conclusively that substrate and inhibitor react with the active 
site cysteines in both subunits of the mtFabH dimer. We have also probed for the first 
time the substrate specificity of the acylation step catalyzed by mtFabH (previous 
analyses have only assessed this step indirectly by analysis of the overall reaction), and 
shown clear preferential formation of a modified enzyme using a C12 dodecanoyl-CoA.  
These findings imply a role for ACPM in determining the specificity of the mtFabH 
reaction and the profile of the product pool and provide new and essential data for the 
formulation of a model for mtFabH catalysis.      
 
4.3 Experimental procedure 
4.3.1 Materials 
Long chain acyl-CoAs, coenzyme-A, imidazole, dithiothreitol (DTT) (Sigma); 
Crystal screens I and II (Hampton Research).  
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4.3.2 Enzyme expression and purification 
The wild type and C112A mtFabH proteins were overexpressed in E. coli as 
discussed in chapter 3. 
 
4.3.3 Synthesis of decylSSCoA 
DecylSSCoA was synthesized using standard procedures83 and generously 
provided by Dr. Mamoun Alhamadsheh. 
 
4.3.4 ESI-MS analysis 
A solution of wild type or mutant mtFabH in sodium phosphate buffer (50 mM, 
pH 7.0, 15 % glycerol) was incubated at room temperature for 40 min with either an 
equimolar  mixture of C6, C8, C10, C14, C16, C18, and C20 acyl-CoAs (ratio of mtFabH 
monomer to each substrate was 1:5) or decylSSCoA (ratio of mtFabH monomer: inhibitor 
of 1:5).  Excess ligand in both incubations was then removed using Pierce spin desalting 
columns and the enzyme concentrated in a Microcon concentrator (50 kDa cutoff) and 
stored at –20˚C until the ESI-MS analysis was performed. The thawed samples were 
diluted to a concentration of approximately 1 pm/µl with 50% methanol/0.1% formic acid 
and analyzed by ESI-MS using a Quadrupole Time-of-flight mass spectrometer under 
standard procedures and the peaks were deconvoluted by the Bayesian protein reconstruct 
tool (in the Bioanalyst QS 1.1 software package).  
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4.3.5 Crystallization conditions (Kindly performed by Dr. Faik Musayev) 
Prior to crystallization trials, the protein solution was concentrated to 
approximately 15mg/ml by ultrafiltration using a Microcon concentrator (Amicon) with a 
30 kDa cutoff. The enzyme (15mg/ml in 100mM sodium phosphate buffer, pH 7.0) and 
inhibitor (13mM in methanol) solutions were mixed in a 1:3 molar ratio and incubated on 
ice for 2 hours. Crystallization of the mtFabH- C10SSCoA was achieved using the 
hanging-drop vapour-diffusion technique.  Initial crystallization conditions were screened 
using Crystal Screen and Crystal Screen II from Hampton Research at 290K.  Crystals 
grew within two-three weeks from PEG-4K and PEG-10K and further variation of 
conditions yielded two optimal crystal forms.   Both were obtained by mixing 2µl of 
protein-inhibitor complex solution with an equal volume of reservoir solution and 
equilibrated over the precipitant well at 295K. The first crystal form was obtained in 25% 
(w/v) PEG-8K, 0.1 M ammonium sulfate and 100mM Na Cacodylate, pH 6.5 and grew to 
maximum dimensions of ~ 0.04 x 0.02 x 0.06 mm within three weeks.  These crystals 
have space group P1, with unit cell parameters a = 49.06, b = 55.76, c = 63.16 A, α = 
92.8 , β = 98.8, γ = 111.80
.
  The second crystal form was crystallized in the presence of 
18% PEG-10K (w/v) and 100mM Na Hepes, pH 7.0 and grew to 0.05 x 0.03 x 0.3mm 
within three weeks.  These crystals have space group C2221 with unit cell parameters a = 
67.65, b = 89.36, c = 232.01 A.   
Data sets for both crystal forms were collected at 100°K on an R-Axis IV++ 
image-plate detector using CuK α X-rays (λ = 1.54 A) from a Rigaku MicroMax TM 
–
 
007 X-ray source equipped with MSC Varimax confocal optics operating at 40kV and 
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20mA. The crystals were transferred with a cryoloop into corresponding mother liquor 
solutions containing additional 15-20% glycerol and 0.1mM inhibitor for ~10s and 
subsequently flash-cooled in a cold nitrogen-gas stream from an X-stream cryosystem 
(MSC). Both crystal forms diffracted to 2.5Å resolution, but the data-collection statistics 
were better for the second crystal form, which was used for structure determination and 
refinement.  Coordinates of the final refined structure were deposited in the RCSB with 
accession number 2QX1.  
 
4.4 Results and discussion.    
4.4.1 Acylation of mtFabH by a mixture of acyl-CoA substrates 
mtFabH was treated with a mixture of acyl-CoA substrates ([C6-C20]-CoA) in the 
absence of ACP and the resultant acylated mtFabH was analyzed using ESI-MS. The 
ratio of each acyl-CoA to the mtFabH monomer is ~ 5:1. The experimental ESI mass 
value for native mtFabH monomer is 36903 Da (compared to a theoretical value of 
36904.7 Da) (Figure 21a).  Treatment of mtFabH with this mixture of acyl-CoAs for 40 
minutes at room temperature resulted in total modification of the enzyme as evident from 
the complete absence of native mtFabH at 36903 Da (Figure 21b).  These data provide 
the first evidence that both monomers of the mtFabH dimer are acylated during reaction. 
The appearance of a major peak at 37085.0 Da corresponds to the addition of one 
dodecanoyl group (from dodecanoyl-CoA) to the mtFabH enzyme (experimental mass 
shift of +182 Da compared to theoretical mass value of +183 Da).  Surprisingly, under 
our assay conditions, we did not observe mtFabH acylation with any other acyl-CoAs.    
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Figure 21: Reconstructed ESI-TOF mass spectra of the incubation products of WT mtFabH with a 
mixture of acyl-CoAs (C6-C20). (a) Mass spectrum of untreated WT mtFabH (control). (b) Mass spectrum 
of WT mtFabH treated with acyl-CoA mixture. 
 
a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b 
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The apparent selective formation of the dodecanoyl product is puzzling given the 
relatively similar rates of reaction for the overall mtFabH catalyzed reaction with a range 
of acyl-CoA substrates.57 However, it is consistent with our repeated observation of 
adventitiously bound dodecanoic acid in the substrate binding channel of crystal 
structures of recombinant mtFabH expressed in E. coli. Also, in trying to prepare 
Michaelis complexes of mtFabH C112A mutant with either tetradecanoyl-CoA or 
hexadecanoyl-CoA for co-crystallization, we have invariably obtained a complex with 
dodecanoyl-CoA in the binding site (unpublished data). We cannot exclude the 
possibility that the tetradecanoyl- or hexadecanoyl- groups are present in the determined 
crystal structures but are disordered at their terminal pairs of methylene groups.  
However, this is made less likely by the determination from HPLC analyses of these 
longer chain acyl-CoA substrate preparations, that a dodecanoyl-CoA impurity (≤2%) is 
present, which we infer binds preferentially to the mtFabH during crystallization.  
Together these observations suggest that the mtFabH Michaelis complex and subsequent 
acyl-enzyme intermediate thermodymamically favor the dodecanoyl-CoA substrate.   
 
4.4.2 Thio-Alkylation of mtFabH by decylSSCoA 
  As noted above, MeSSCoA inhibits ecFabH through a disulfide exchange 
mediated transfer of the MeS- group to the sidechain sulfur of the active site Cys112 of 
the enzyme. We also prepared decylSSCoA, which in preliminary experiments did not 
inhibit ecFabH but was effective against mtFabH.83 To determine whether this class of 
inhibitors acts by the same mechanism on mtFabH as on ecFabH, the inhibition of 
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mtFabH by decylSSCoA was analyzed using ESI-MS under similar conditions to those 
described above for the acylation reaction (Figure 21).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S S CoA
C10H21S
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experimental 176 Da            
              
 
Figure 22: Reconstructed ESI-TOF mass spectra of the incubation mixture of WT mtFabH and 
decylSSCoA. (a) Mass spectrum of untreated WT mtFabH (control) (b) Mass spectrum of WT mtFabH 
treated with decylSSCoA disulfide inhibitor.  
a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b 
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 Treatment of mtFabH with decylSSCoA resulted in formation of a modified 
mtFabH species (Figure 22B) that correlates well with the addition of a C10S- fragment (a 
theoretical mass increase of 173 Da to the mtFabH monomer fragment). The absence of 
this peak in C112A mtFabH mutant confirmed that this modification occurs at the active 
site cysteine in WT mtFabH (data not shown). Only a fractional modification of the 
mtFabH with decylSSCoA was observed, in contrast to the full modification observed 
using dodecanoyl-CoA. This observation, taken with the 23% extent of reaction for 
decanoyl-CoA with mtFabH,57 confirm a specificity preference for C12 over C10  ligand 
binding in the acyl binding channel, but probably also reflects in part a slower reaction 
rate of the inhibitor relative to the substrate. This latter is the case for acetyl-CoA and 
methylSSCoA inhibitors with ecFabH.83  
A co-crystal structure of mtFabH and decylSSCoA showed both of the active site 
cysteines of the mtFabH dimer to be modified through disulfide linkage to the decylthio- 
group. The decyl group has full occupancy in one subunit and slightly less than full 
occupancy in the second subunit. As we and others have frequently observed, CoASH 
product is only weakly retained in the pantetheinate channel of FabH – ligand complex 
structures. No interpretable density for CoASH was observed in one subunit of the 
decylSSCoA complex, while density in the other subunit was largely complete except for 
breaks around the pyrophosphate group. CoASH is probably preferentially retained in 
this latter channel as a consequence of an interaction of the pyrophosphate group of the 
nucleotide with Arg214 of a symmetry-related molecule. The terminal thiol of the 
pantetheinate group of this CoASH is 6.1Å from the Cys112 decyl-disulfide and the 
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terminal adenine nucleotide group stacks on Trp32 and Arg151 at the mouth of the 
binding pocket (Figure 23), as has been observed in other CoASH complexes with FabH.   
 
 
 
 
 
 
 
 
Figure 23.  Backbone structure of mtFabH homodimer (subunits in gold and magenta ribbon) in 
complex with C10S- (space filling, cyan = carbon, red = oxygen, blue = nitrogen, orange = sulfur) 
covalently linked to the sidechain sulfur of Cys112 (also space filling) in both subunits.  CoA is 
shown bound in only the A-subunit (gold) also in space filling model. 
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4.5 Conclusion 
We provide the first evidence that the active site cysteine in both subunits of the 
wild type mtFabH dimer is able to react with either a dodecanoyl-CoA substrate or a 
decylSSCoA inhibitor. The data clearly demonstrate that binding and reaction at one 
subunit does not preclude reaction at the other, but we cannot determine whether binding 
and reaction occur at the same rate in both subunits. In the case of ecFabH, reaction at the 
second subunit is slower than that at the first.83  
In the static crystal structure of wild type mtFabH modified by formation of a 
disulfide product with the decylSSCoA inhibitor, the CoA binding channel is the only 
obvious access path to the buried acyl-binding channel. Binding and reaction of one of 
the mtFabH subunits with substrate or inhibitors via a reptational threading through this 
pantetheinate channel and past the active site residues would be energetically 
unfavorable. The data however show that this occurs readily to both subunits suggesting 
that there is likely an alternative more favorable pathway for binding of substrate or 
inhibitor ligand to mtFabH. These observations support the existence of a hitherto 
unobserved ‘open’ form of mtFabH, like that proposed for ecFabH,63,83 which provides a 
direct, low energy path for substrate or inhibitor entry to the acyl binding channel.   
The overall mtFabH catalyzed reaction using malonyl-ACPM has been shown to 
use C14-C20 acyl-CoAs at least as efficiently as dodecanoyl-CoA.57 In this current work 
we have shown that in the acylation reaction performed with a range of acyl-CoAs 
(carried out in the absence of malonyl-ACPM) the mtFabH selectively forms a product 
with the dodecanoyl CoA. It has been previously proposed that ACPM modulates the 
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substrate specificity of the mtFabH.57 Our current data support this hypothesis and we 
propose that ACPM assists in formation of an open mtFabH structure, which facilitates 
both binding of longer chain acyl-CoA substrates and also release of the long chain β-
ketoacyl-ACP products.    
In conclusion, this and other recent analyses of FabH enzymes suggest that the 
model for catalysis provided by current crystal structures is incomplete, and must be 
expanded to include significant protein conformational changes which are associated with 
the acyl–CoA and specific malonyl-ACP substrates. Further experiments are discussed in 
future direction (chapter 7).  
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5. Separate entrance and exit portals for ligand traffic in Mycobacterium 
tuberculosis FabH 
 
5.1 Summary 
Mycobacterium tuberculosis FabH initiates type II fatty acid synthase-catalyzed 
formation of the long chain (C16 – C22) acyl-CoA precursors of mycolic acids, which are 
major constituents of the bacterial cell envelope. Crystal structures of mtFabH (as 
discussed in chapter 3) show the substrate binding site to be a buried, extended L-shaped 
channel with only a single solvent access portal. The distal, dead end arm of this channel 
binds the acyl moiety of the substrate and the arm proximal to the solvent portal binds the 
CoA moiety. Entrance of an acyl-CoA substrate through the solvent portal would require 
energetically unfavorable reptational threading of the substrate to its reactive position.  
Using a new class of FabH inhibitors, we have tested the alternative hypothesis that FabH 
exists in an ‘open’ form during substrate binding and product release, and a closed form 
in which catalysis and intermediate steps occur. This hypothesis is supported by mass 
spectrometric analysis of the product profile and crystal structures of complexes of 
mtFabH with these inhibitors.      
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5.2 Introduction: 
The crystal structure of the Michaelis complex of lauroyl-coenzyme A with an 
inactive C112A mtFabH mutant (chapter 3) clearly shows substrate bound in an “L” 
shaped channel of each monomer (Figure 24a), with the active site triad (Cys112-His244-
Asn274) at the junction of the two arms of the “L” (Figure 24 b). Coenzyme A occupies 
the solvent accessible, pantetheinate arm of the “L”, while the acyl group occupies the 
distal, dead-end arm of the “L”, an extended hydrophobic channel that appears accessible 
Figure 24: (a) Backbone structure of C112A mtFabH homodimer (gold ribbon) in complex with 
lauroyl-CoA (space filling, green = carbon, red = oxygen, blue = nitrogen, yellow = sulfur, magenta 
= phosphorous) bound in the buried, L-shaped binding site of each monomer of the dimer. 
(adopted from chapter 3)  
(b) Expansion of active site residues (gold stick) in 24 (a) with functional atoms (color coded as in 
Figure 24 a) and Cys112 modelled from wt mtFabH structure for the lauroyl-CoA (space filling 
atoms color coded as in Figure 24 (b) with bound lauroyl-CoA.     
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only through the pantetheinate channel. Binding of lauroyl-CoA substrate would thus 
appear to require migration of the hydrophobic lauroyl chain through the pantetheinate 
binding channel and around the bend of the “L” past the hydrophilic and charged 
catalytic residues. Formation of the complex in this manner would present formidable 
stereochemical and energetic barriers, and dissociation of long chain β-ketoacyl-ACP 
reaction product from this buried hydrophobic site via a reversal of this process would 
appear to be equally unfavorable.   
These considerations have led us to hypothesize that native mtFabH adopts a 
hitherto unobserved ‘open’ conformation which offers an alternate pathway with lower 
energy barriers for initial substrate binding and final product release. To test this 
hypothesis, we prepared inhibitors with one or two hydrophobic arms that occupy either 
one or both binding channels, and a reactive group that targets the active site cysteine 
(Figure 25). The binding modes of these inhibitors with the wild type mtFabH have been 
established by mass spectrometry and x-ray crystallography. These same analyses with an 
mtFabH A246F mutant, whose pantetheinate binding channel is blocked, reveal that 
inhibitor binding and reaction still proceed efficiently, but only with one arm inhibitors 
that bind exclusively in the acyl channel. These experiments provide strong evidence that 
mtFabH exists in an open conformation that accepts ligands directly into the acyl binding 
channel without entry to the single solvent portal and passage through the pantetheinate 
channel of the closed form of the enzyme. These results support a new model for 
substrate binding, catalysis and product release in mtFabH.   
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5.3 Experimental procedures 
5.3.1 Materials 
All general chemical supplies not listed below are ordered from standard 
companies and were reagent grade or better. The source of specific supplies are as 
follows: [2-14C] malonyl-CoA (ARC-528, specific activity 55mCi/mmol) was purchased 
from American Radiolabeled Company and lauroyl-CoA (trilithium salt) was purchased 
from Sigma. The Reverse Phase (RP) HPLC studies were performed on Amberchrom C18 
RP columns from Rohm and Hass Company; trypsin enzyme used was proteomic grade 
and was bought from Sigma; PepcleanTM C18 Spin Columns were from Pierce. All 
Electrospray Ionization Mass spectrometry (ESI-MS) experiments were performed on 
Quadrupole time-of-flight mass spectrometer (model QSTAR XL) from Applied 
Biosystems/MDS Sciex which is equipped with a standard ion source from MDS Sciex, 
Concord, Canada. The glu-fibrinopeptide used for externally calibrating the QSTAR 
instrument in positive ion mode was from Sigma. Grafit 4.012 (Middlesex, United 
Kingdom) for data plotting is bought from Sigma. 
 
5.3.2 Enzyme expression and purification: 
WT mtFabH and C112A mtFabH are cloned, expressed and purified as described 
in chapter 3. The A246F mutations were made on the open reading frame Rv0533c 
(mtFabH), which was cloned into the expression vector pET-15b as described 
previously.27  Mutants were made according to the protocol provided for the Quikchange 
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XL site-directed mutagenesis kit and primers designed to substitute Phe for Ala246.  
Primers were ordered from Integrated DNA Technologies and were, forward 5’-GTG 
TTC GTC CCT CAT CAG TTC AAT AGC CGC ATC AAC GAG - 3’ and reverse 5’ –
CTC GTT GAT GCG GCT ATT GAA CTG ATG AGG GAC GAA CAC– 3’. Mutations 
were confirmed by sequence analysis of the final constructs. The plasmid was purified 
using the QIAprep miniprep kit.  
  Competent E. coli BL21DE3 Codon Plus cells were transformed with pET-15b 
carrying A246F FabH insert.  Transformants were grown in LB medium to an absorbance 
of 0.4 – 0.6, induced with 0.2 mM isopropyl-beta-D-thiogalactopyranoside, and 
incubated for an additional 4 hrs at 37º C.  Cells were harvested by centrifugation at 
10,000 g for 10 min. at 4 °C and stored at -80 °C until used.  After lysis with lysozyme on 
ice for 30 minutes, cells were sonicated on ice and then centrifuged at 12,000 g for 30 
min. at 4 °C. The supernatant was loaded onto a Hitrap chelating 5-ml column and 
washed with a gradient step from 0 to 120 mM imidazole in 50mM sodium phosphate 
buffer, pH 8.0 with 300mM sodium chloride. FabH was eluted with 1 M imidazole under 
the same buffer conditions. The high concentration of imidazole employed in the washing 
step improves the homogeneity of the mtFabH band as assessed by SDS-PAGE analysis. 
The mtFabH was desalted in 100mM sodium phosphate buffer pH 7.0, and kept at 4 °C 
overnight. Protein was concentrated in Centricon tubes and assayed by Bradford assay 
using BSA as standard. For crystallization, the concentration of mtFabH used was in the 
range of 4 - 8 mg/ml. 
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5.3.3 Synthesis of compounds 1-3: 
The syntheses of inhibitors 1-3 were carried out by Dr. Alhamadsheh and kindly 
provided in ample amount for this study. 
 
5.3.4 Enzyme assays:  
The mtFabH assay was performed as described in chapter 2.  
 
5.3.5 Electrospray Ionization-Mass Spectrometry (ESI-MS) analysis:  
5.3.5.1 Sample preparation:  
 
Wild type or mutant mtFabH in sodium phosphate buffer 50 mM, pH 7.0, 15 % 
glycerol were first desalted with HPLC grade water using Hitrap desalting column. The 
aliquot of enzyme (10-40 µM) and inhibitors 1, 2 or 3 separately (mtFabH dimer: 
inhibitor ~ 1:10) were incubated at room temperature for 60 minutes and then excess or 
non-covalently adhered inhibitor was desalted using a Pierce spin desalting columns. The 
enzyme was concentrated using Microcon concentrator (50 kDa cutoff) that also works as 
second desalting step and then stored at –20˚ C until the ESI analysis.  
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5.3.5.2 ESI-MS analysis conditions:  
The sample was diluted to 1 pm/µl with 50 % methanol/0.1 % formic acid and 
analyzed by a quadrupole time-of-flight mass spectrometer. The instrument was 
externally calibrated in the positive ion mode using two fragment ion peaks (m/z 
175.1190 and m/z 1285.5444) from the tandem mass spectrum of Glu-fibrinopeptide. The 
samples were directly infused into the ion source using a 500 µl syringe at a flow rate of 
5 µl/min through red peek tubing (Upchurch). The following parameter settings were 
used to acquire mass spectra from m/z 600-1600 in the positive ion TOF/MS mode: spray 
voltage, 5500V; curtain gas, 20; GS1 gas, 15; declustering potential (DP), 85 V; 
declustering potential 2 (DP2), 15 V; focusing potential (FP), 265 V; accumulation time, 
1 s. Typically, spectra were averaged over 120 scans, and the series of multiply charged 
ion peaks were deconvoluted by the Bayesian protein reconstruct tool (in the Bioanalyst 
QS 1.1 software package) to determine the zero charge masses of the intact proteins. For 
all mass calculations, 0.01 % mass accuracy was set as tolerance limit; ie about 3.7 Da 
for mtFabH whose monomeric molecular weight is about 37,000. 
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5.3.5.3 ESI-MS data analysis: 
The theoretical mass of His-tagged WT mtFabH monomer by DNA deduced 
amino acid sequence is calculated to be 36904.7 Da. The experimental mass is found to 
be 36903 as shown in Figure 26 a. Treatment of mtFabH with inhibitors resulted in 
appearance of multiple new species along with their sodium adducts (Figure 26b). The 
mtFabH was purified and initially prepared in sodium phosphate buffer and thus up to 4 
sodium adducts were readily obtained as evident from the control experiment (untreated 
WT mtFabH deconvoluted spectrum, Figure 26 a). All calculations were performed based 
on guidelines set forth as described below. The area of most abundant species was 
identified and all species with areas encompassing up to 10% of its area was taken into 
consideration for calculation of total area. Mass value of control mtFabH (36903 Da) was 
subtracted from each mass value obtained and the positive mass difference as indicative 
of a particular species being present. Each species and its sodium adducts was 
categorized as a single species and percent area of each species was calculated. Mass 
differences of more than 1 kDa and negative mass differences were discarded as non-
mtFabH related species. The final data was presented with nature of species (unmodified, 
trimodified, dimodified, mono-modified and others, for those which can’t be assigned) on 
X-axis and percentage of particular species observed is plotted on Y-axis.  
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5.3.6 Crystallization, x-ray data collection and structure determination. (This work 
was carried out by Dr. Faik Musayev, Dr. Tonie Wright and Dr. J. Neel Scarsdale)  
Crystals were obtained by the hanging-drop vapor diffusion method using 4µl 
drops consisting of a 1:1 ratio of protein to reservoir solution equilibrated against 600µl 
of reservoir solution at room temperature. Protein concentration varied from 4-15mg/ml 
in 100mM sodium phosphate buffer, pH 7.0. Inhibitor molecules were dissolved in 
methanol to a final concentration of 34mM (1), 25mM (2) and 23mM (3) and mixed with 
protein solution at the molar ratios shown in Table 5. Before crystallization, protein-
inhibitor complex mixtures were incubated on ice for 2 hrs. Crystallization conditions 
and lattice parameters for the structures are summarized in Table 5. 
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Table 5 Crystal conditions for structures determined in this study (chapter 5) 
 
Inhibitor          Protein Protein Protein: Reservoir solution              Lattice Parameters               Accession No.       
                    Conc.          Inhibitor                                      
No.                                         molar      (A)         
                                              (mM) ratio 
 
 
 
1                    WT 0.21 1:3.5 50mM Na Acetate, pH4.6,                68.03, 88.85, 229.74            2QNZ 
    2.4M Na Formate                             sp.gr. C2221 
 
1                    A246F 0.11 1:4 100mM Na Hepes, pH 7.5,               67.70, 88.69, 229.90            2QNY 
    1M K/Na Tartrate                              sp.gr. C2221 
 
2                    WT 0.15 1:5 100mM Na Mes, pH 6.5,                   68.28, 88.98, 230.25           2QNX 
    50mM NaH2PO4/KH2PO4,              sp.gr. C2221 
                                                                                    1.8M NaCl 
 
3                    WT 0.4 1:2.5 100mM Na Hepes, pH 7.5,               68.41, 89.12, 233.29           2QO1 
    1M K/Na Tartrate                              sp.gr. C2221 
 
3                   A246F 0.21 1:4 100mM Na citrate, pH 5.6,                55.30, 93.05, 104.72           2QO0 
    10% Isopropanol, 18% PEG-4K        sp.gr. P212121 
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For x-ray data collection, crystals were cryoprotected in their mother liquid 
solution supplemented with 25-30% glycerol, and where appropriate, with inhibitors, 
before flash cooling in a liquid nitrogen stream. X-ray data were collected at 100oK using 
a Molecular Structure Corporation (MSC) X-Stream Cryogenic Crystal Cooler System 
and an R-Axis IV++ image plate detector with a Rigaku MicroMaxTM–007 X-ray source 
equipped with MSC Varimax confocal optics operating at 40 kv and 20 mA. Data were 
processed and scaled with D*Trek. Structures were determined via molecular 
replacement with AMORE, using pdb entry 1HZP27 as a search model, and refined via 
alternating cycles of manual fitting into SigmaA weighted 2mfodfc electron density maps 
in COOT84 and computational refinement in CNS71 and Refmac585. Ligand topology and 
parameter files used in refinement were generated using the prodrg server.86 Data 
collection and refinement statistics are summarized in Table 6. 
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Table 6: Data Collection and Refinement Statistic for MtFabh Crystal Structures 
 2QNZ 2QNY 2QNX 2QO1 2QO0 
Data Collection       
Resolution(Å) 48.3-2.3 (2.3-2.3)5 39.2-2.1 (2.2-2.1)5 29.0-2.7 (2.8-2.7)5 39.7-2.6 (2.7-2.6)5 38.0-1.8 (1.9-1.8)5 
Unique Reflections 31228 (2987)5  35143 (2605)5 19219 (1913)5 20938 (2193)5 46884 (4610)5 
Redundancy 12.43 (7.98)5 3.17 (1.95)5 3.65 (3.69)5 2.54 (2.84)5 6.37 (6.17)5 
Rmerge6 0.089 (0.206)5 0.075 (0.150)5 0.120 (0.264)5 0.108 (0.244)5 0.095 (0.314)5 
Completeness(%) 99.3 (96.7)5 92.2 (69.6)5 97.3 (98.0)5 93.2 (98.8)5 99.8 (99.9)5 
I/σ(I) 19.6 (9.5)5 10.7 (4.4)5 8.7 (4.8)5 7.4 (4.1)5 11.3 (5.5)5 
Refinement      
Resolution 14.8-2.3 (2.3-2.3)5 10.0-2.1 (2.2-2.1)5 15.0-2.7 (2.8-2.7)5 15.0-2.6 (2.6-2.6)5 25.0-1.8 (1.9-1.8)5 
Number of reflections (work) 27984 (1943)5 31289 (1625)5 17172 (1209)5 18707 (1459)5 42064 (3050)5 
Number of reflections (test) 3115 (207)5 3445 (182)5 1954 (147)5 2076 (146)5 4710 (368)5 
Rwork/Rfree7 0.16/0.2 (0.19/0.25)5 0.19/0.24 (0.2/0.27)5 0.2/0.2 (0.2/0.3)5 0.2/0.29 (0.28/0.35)5 0.19/0.26 (0.31/0.37)5 
Average B(Å2) 28.9 30.2 26.8 40.5 22.9 
DPI(Å)8 0.212 0.213 0.352 0.389 0.162 
                                                          
5
 Values in parentheses are for highest resolution shell. 
6
 Rmerge = ∑ |Ih – ‹I›|/‹I› where Ih refers to the measured intensity for a given reflection and ‹I› refers to the average measured intensity for that reflection. 
7
 Rwork = ∑ |Fobs – Fcalc|/ ∑Fobs where Fobs and Fcalc refer to the observed and calculated structure factors respectively. 
8
 DPI = (Natoms/Nobs)1/2c–1/3dminRfree where Natoms is the number of atoms in the refinement, Nobs is the number of reflections, c is the data set completeness expressed as a 
fraction, dmin is the resolution and Rfree is the free R factor. 
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Deviations from Ideality 2QNZ 2QNY 2QNX 2QO1 2QO0 
Bond Lengths 0.007 0.007 0.007 0.007 0.009 
Bond Angles 1.11 1.08 1.11 1.10 1.22 
Ramachandran Plot      
Most Favored (%) 90.7 90.1 88.1 88.8 90.5 
Additional Allowed (%) 9.0 9.1 11.3 10.4 9.0 
Generously Allowed (%) 0.2 0.4 0.4 0.5 0.4 
Forbidden(%) 0.2 0.4 0.2 0.4 0.2 
Table 6: Data collection and refinement statistic for mtFabh crystal structures in chapter 5 (continued…). 
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5.4 RESULTS 
5.4.1 Inhibitor design and activity 
 
  
 
 
 
It has been demonstrated that alkyl-CoA disulfide inhibitors target the active site 
cysteine of both ecFabH and mtFabH and that inhibition of these enzymes is specific for 
short (C2) or long (C10) alkyl chains respectively, matching their acyl chain substrate 
 
Figure 25: Chemical structures of inhibitor ligands used in this study 
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specificities.83 To investigate the route for ligand binding and reaction with mtFabH, we 
synthesized linear inhibitors (Compounds 1-3, Figure 25) composed of two arms linked 
by an oxycarbonyl-disulfide group, which can potentially react with the reactive site 
Cys112 by acylation or by thiol-disulfide exchange. The arms in the compounds used 
here are: ethanol, decyl and decanoic acid. Each pair of arms of a compound is 
potentially able to simultaneously bind in the acyl and pantetheinate binding channels of 
mtFabH.  Preliminary analysis under standard conditions revealed similar levels of 
inhibition for mtFabH (IC50 values: 1, 3.8 ± 0.5 µM; 2, 2.4 ± 0.8 µM; 3, 2.7 ± 0.2 µM).  
 
5.4.2 Characterization of E-I complex: 
We initially utilized the “reversibility studies” to analyze the nature of association 
between mtFabH and compounds 1-3 and the results are recorded in Appendix 1. The 
studies revealed the formation of a covalent adduct, most likely via a disulfide bond, 
between the two. We further utilized the “bottoms up” type proteomics approach 
(digestion of E-I complex with trypsin followed by HPLC/ tandem MALDI-MS) to 
investigate the specific mtFabH residue/s modified on reaction with 1 and 2. Indeed, we 
observed the modification at Cys23 residue (on the surface of the mtFabH), but could not 
prove the reaction at the active site Cys112 (as proposed), most likely due to the harsh 
and long digestion conditions (Appendix 1). We thus diverted our attention to intact 
protein ESI-MS techniques to investigate the reaction under relatively milder conditions. 
The ESI-MS data complemented with crystal structures revealed the reaction at active 
site Cys112 and also threw light on the mode of binding of the inhibitors. 
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5.4.3 Electrospray ionization mass spectrometry and crystal structure analysis: 
5.4.3.1 Reaction products and crystal structures of mtFabH and C112A mtFabH 
with 1   
Electrospray ionization mass spectrometry (ESI-MS) was used to follow the 
modification of the wild type mtFabH with an excess of 1. Under these conditions the 
protein was completely modified (Figure 26b vs 26a and Figure 36a), the two major 
species exhibiting mass increases of either 230 or 338 Da.  The former of these is 
consistent with addition of three 77 Da fragments of A (theoretical increase in mass of 
231 Da) to mtFabH monomer, while the latter is consistent with addition of two 77 Da 
fragments of A, and one 185 Da fragment of B (theoretical increase in mass of 339).  
These analyses indicated that all three solvent accessible cysteines in wild type mtFabH 
(the active site Cys112, plus Cys23 and Cys154) can react with 1 through disulfide 
exchange and at least one through acylation.   
The crystal structure of the inhibition complex of wt mtFabH with 1 showed extra 
electron density at the two surface cysteines (Cys23 and Cys154), consistent with 
disulfide linked beta-mercaptoethanols, and at the active site Cys112, consistent with 
acylation by the long B arm fragment of 1.  This crystal structure corresponds to the tri-
modified reaction product denoted (A + A + B) identified by mass spectroscopy (the  
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+ 339 Da  (B+A+A) 
+ 231 Da (A+A+A) 
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b 
 
 
Mass (Da) 
 
Figure 26: Reaction products of WT mtFabH with 1. a) Reconstructed ESI-MS spectrum of untreated WT 
mtFabH (Control) b) Mass spectrum of WT mtFabH treated with 1. The mass shifts in WT mtFabH on 
treatment with 1 is correlated with proposed species (in bracket). WT mtFabH is treated with excess of 1 and 
incubated at room temperature for 60 minutes. The mixture is desalted to remove the excess inhibitor and the 
species formed are determined using direct infusion ESI-TOF mass spectrometry as determined in material 
and methods. 
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A + A + A tri-modified species did not crystallize).  The contiguous electron density in 
both mtFabH subunits extending from the active site Cys112 into both acyl and 
pantetheinate binding channels (Figure 27a) was interpreted and refined as dual, 
conditional half occupancy of each channel by fragment B of compound 1, whose 
carbonyl carbon forms a thioester with the active site Cys112 sidechain –SH.     
 
 
 
Figure 27 a: Stereoview of structure around the binding channel of the product complex of compound 1 with 
the wild type mtFabH, showing fragment B of  its electron density alternately bound in each of the two arms, 
the acyl channel (A) and the pantetheinate channel (P), of the substrate binding channel.  Contour level of 
electron density is 1σ. b). Structure of the A246F mutant with a phenylalanine residue blocking the 
pantetheinate channel (gray space filling surface) and fragment B (2 conformations) of compound 1 bound in 
the acyl channel.   
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The two complexes in the asymmetric unit (one with fragment B in the acyl 
channel, the other with B in the pantetheinate channel), both acylated on Cys112, differ 
from each other in the interactions they make at the active site. Furthermore, each differs 
in detail from its counterpart (with the ligand in the same channel) in the other subunit of 
the mtFabH homodimer complex.   
The carbonyl group of the complex with fragment B in the acyl channel of one of 
the two subunits of the asymmetric unit is oriented toward the oxyanion hole, but does 
not make the full complement of hydrogen bonds. The carbonyl oxygen makes a 
hydrogen bond to the main chain –NH- of Ala306 but not to the –NH- of Cys112 in 
either subunit.  In one subunit this oxygen makes a long hydrogen bond to the sidechain 
of Ser276.  In the other subunit the Ser276 sidechain has alternate conformations, both of 
which make favorable (2.6Å) hydrogen bonds to the ester oxygen of the ligand in the acyl 
channel. These hydrogen bonds to the Ser276 sidechain –OH may compensate for the 
absence of the hydrogen bond to the main chain –NH- of Cys112 in the oxyanion hole.     
For the complex with the ligand bound in the pantetheinate channel, the carbonyl 
oxygen in one subunit makes a hydrogen bond with the sidechain –NH2 of Asn274 (3 Å), 
but not to His244, the two residues that constitute the malonyl anion-binding site.  In the 
second subunit this oxygen makes tenuously long hydrogen bonds (3.3 Å and 3.6 Å 
respectively) to these groups in the malonyl anion site, but makes a favorable hydrogen 
bond (2.5 Å) to the sidechain of Ser276 in one of its two alternate conformations.      
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+ 153 Da (A+A) 
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Figure 28: Reaction products of C112A mtFabH with 1. a) Reconstructed ESI mass spectrum of untreated 
C112A mutant mtFabH (Control) b) Mass spectrum of C112A mutant mtFabH treated with excess of 1. 
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ESI-MS analyses of the C112A mutant complex prepared under the same 
conditions showed no tri-modified species (Figure 28 and 36a).  Instead, a predominant 
di-modified species (mass increase of 152 Da) was observed, consistent with addition of 
two 77 Da fragments of A. Two less abundant species (mono- and di-modified), 
consistent with the addition of a single B fragment and an A+B respectively, that together 
approximated the unmodified species in abundance (Figure 36 a), were also observed.    
This decrease in the number of cysteine modifications coincident with mutation of the 
active site Cys112 indicates that it is this residue in the wild type mtFabH that can 
undergo modification with either fragment A or B. 
 
5.4.3.2. Reaction of A246F mtFabH with 1   
The alternate occupancy of the acyl- and pantetheinate channels of wild type 
mtFabH by the C10H21OCO groups in the above structures could be realized by two 
binding orientations of 1 prior to reaction with the active site Cys112. The alternate 
occupancy might also arise if there was only one binding orientation which permitted 
reaction with C112, with a subsequent equilibration of the covalently-linked C10H21OCO 
chain between the two channels.    
In either case, migration of the inhibitor into the pantetheinate channel with 
passage through the active site residues into the acyl channel, presents similar formidable 
energetic barriers to those facing the natural acyl-CoA substrate, which suggested to us 
that there may be alternative modes for substrate and ligand entry to the extended 
mtFabH binding site.   
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+ 338 Da (B+A+A) 
+ 230 Da (A+A+A) 
 
+ 154 Da (A+A) 
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Figure 29: Reaction products of A246F mtFabH with 1. a) Reconstructed ESI mass spectrum of 
untreated A246F mutant mtFabH (Control) b) Mass spectrum of A246F mutant mtFabH treated with 
excess of 1. 
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To test this hypothesis we created an A246F mutant mtFabH, which introduces a 
large obstructive group into the pantetheinate channel about 8 – 9Å out from the active 
site Cys112.  This A246F mtFabH mutant had no detectable catalytic activity in an 
elongation assay with lauroyl-CoA and malonyl-ACP.  Mass spectrometry (Figures 29 
and 36a) revealed that an incubation of 1 with this A246F mutant resulted in the same tri-
modification seen with the wild type enzyme.  Both tri-modified species (A + A + A) and 
(A + A + B) were observed, with an apparent greater abundance of the latter.        
 The crystal structure of the unliganded A246F mutant showed no significant 
differences in structure relative to the wild type except for the presence of the bulky 
phenylalanine, which clearly blocks access to the active site cysteine via the 
pantetheinate channel.  Electron density was observed in the acyl channel that can be fit 
with a free laurate (not linked to the active site cysteine).  Like other mtFabH structures 
crystallized in the absence of ligands, including the wild type, the electron density in the 
acyl channel that can be fit with a free laurate is probably taken up during expression and 
purification of the recombinant mtFabH.   
The co-crystal structure of A246F mtFabH with 1 (Figure 27b) shows the overall 
structure of the protein to be virtually identical to the unliganded mutant.  The 
hydrophobic ligand, modeled as laurate in the acyl binding channel of the unliganded 
A246F crystal structure, is replaced in the liganded form by electron density contiguous 
with Cys112 that can be well fit by fragment B  of 1 in thioester linkage with Cys112 
(Figure 27b).  There was no ligand electron density in the blocked pantetheinate channel.   
In contrast to fragment B in the acyl channel of wt mtFabH, the carbonyl group of B in 
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the A246F mtFabH complex assumes two alternate orientations, one toward the oxyanion 
hole and the other toward the malonyl anion binding site.  In one subunit, the carbonyl 
oxygen makes hydrogen bonds with optimal stereochemistry to –NH- of Cys112 and 
Ala306 in the oxyanion hole of the acyl- binding site, while in the other subunit the 
hydrogen bond to –NH- of Cys112 is too long to be significant.  In both subunits of the 
dimer, the alternative conformation of the carbonyl oriented toward the malonyl anion 
binding site positions the oxygen at long hydrogen bond distance from the His244 and 
Asn274 proton donors.  
The vacant pantetheinate channel in the A246F mutant confirms that this channel 
is blocked by the phenylalanine mutation and indicates that 1 must enter the acyl binding 
channel by a path other than the pantetheinate channel.  We hypothesize that this 
alternative path exists in an ‘open’ form of the enzyme in which the extended binding site 
consisting of the two channels is accessible to ingress of the inhibitor as a result of the 
lifting of a loop that covers both binding channels (see Discussion below).    
 
5.4.3.3 Reaction of mtFabH, C112A mtFabH and A246F mtFabH with 2 and 3   
Inhibitor 1 contains only one long hydrophobic arm, which as shown above can 
occupy either channel of wt mtFabH, or just the acyl binding channel of the A246F 
mutant.   To probe how inhibitors with two hydrophobic arms, in principle competent to 
bind both channels, would react with the A246F mutant, we synthesized 2 and 3, both 
with two long arms differing only in the addition of a carboxylate group to the C10 alkane 
chain.  In addition to providing potential full occupancy of both channels of the enzyme, 
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the anionic carboxylate of 2 and 3 was expected to both inhibit the putative transit of the 
long chain through the pantetheinate channel and into the acyl channel and to direct 
ligand orientation according to the relative hydrophobicities of the two arms and the two 
arms of the binding channel.  
The reaction of wt mtFabH with 2 (Figures 30 and 36b) resulted in two tri-
modified products with mass increases of either 617 Da or 648 Da.  The former is 
consistent with addition of two 217 Da A’ fragments and one 185 Da B’ fragment and the 
latter to addition of three 217 Da A’ fragments (an overall increase in theoretical mass of 
619 Da or 651 Da respectively) per mtFabH monomer. There was no detectable 
unmodified protein. Reaction of 3 with wt mtFabH gave predominantly the tri-modified 
products exclusively with A” chain fragment (some A” + A” di-modified species was 
also observed).    
Crystal structures of the wild type enzyme with 2 and 3 showed that in both cases 
a disulfide species was formed between the A’ or A” fragments and the active site 
Cys112 (Figures 37a and 37 b respectively).  In the structure of mtFabH with 2, the 
undecanoic acid group surprisingly is in the acyl channel and the O-
undecylcarbonothioate lies in the pantetheinate channel, detached from the C112-
disulfide-linked undecanoic acid, and with its carbonyl oxygen oriented towards the 
malonyl anion binding site of His244 and Asn274 (Figure 37a).  Hydrogen bonds in this 
binding site are close to optimal in one subunit (2.72Å and 2.74Å), but are long in the 
other subunit (3.34Å and 3.45Å).  The crystal structure of wild type mtFabH complexed 
with 3 (Figure 37b) shows the decyl  
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Figure 30: Reaction products of WT mtFabH with 2. a) Reconstructed ESI mass spectrum of untreated WT 
mtFabH (Control) b) Mass spectrum of WT mtFabH treated with excess of 2. 
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Figure 31: Reaction products of C112A mtFabH with 2. a) Reconstructed ESI mass spectrum of untreated 
C112A mutant mtFabH (Control) b) Mass spectrum of C112A mutant mtFabH treated with excess of 2. 
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Figure 32: Reaction products of A246F mtFabH with 2. a) Reconstructed ESI mass spectrum of untreated A246F 
mutant mtFabH (Control) b) Mass spectrum of A246F mutant mtFabH treated with excess of 2. 
 
   
  
104 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
+175 Da (A”) 
+348 Da (A”+A”) 
+520 Da (A”+A”+A”) 
a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b 
 
 
Mass (Da) 
 
Figure 33: Reaction products of WT mtFabH with 3. a) Reconstructed ESI mass spectrum of untreated WT  
mtFabH (Control) b) Mass spectrum of WT mtFabH treated with excess of 3. 
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Figure 34: Reaction products of C112A mtFabH with 3. a) Reconstructed ESI mass spectrum of untreated C112A 
mutant mtFabH (Control) b) Mass spectrum of C112A mutant mtFabH treated with excess of 3. 
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Figure 35: Reaction products of A246F mtFabH with 3. a) Reconstructed ESI mass spectrum of untreated 
A246F mutant mtFabH (Control) b) Mass spectrum of A246F mutant mtFabH treated with excess of 3. 
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chain in the acyl channel disulfide linked to Cys112. The O-
carboxyundecylcarbonothioate in the pantetheinate channel is present in the same 
orientation as the O-undecylcarbonothioate group in the complex with 2 with its 
carboxylate at the mouth of the pantetheinate channel and its carbonyl oriented toward 
the malonyl anion binding site, but too far from His244 and Asn274 in both subunits to 
make hydrogen bonds.  This latter difference vis a vis the complex with 2 may be a 
consequence of lattice interactions of the carboxylate that are transmitted to the other end 
of the chain in the malonyl anion binding site.     
These observations demonstrate that the linkage positions of the undecanoic acid 
chain and the decyl chain in 2 and 3 do not determine the orientation of binding these 
compounds in the acyl site of mtFabH.  For 2 the binding of the undecanoic acid in the 
acyl binding channel is possibly stabilized by the presence of the Arg2024 side chain at 
the top of the acyl channel in both subunits (4 – 5Å from the carboxylate).  In one 
subunit, there is also a hydrogen bond between one of the carboxylate oxygens (inferred 
to be in the protonated state) and the amido oxygen of the side chain of Gln191.  The 
recurrence of disulfide exchange products in both cases where the inhibitor has two long 
arms suggests that orientation in binding is determined primarily by the positioning of the 
oxycarbonyl-disulfide group in the active site. The crystal structures show that the 
carbonyl oxygen of this group is directed toward the malonyl anion binding site, and this 
may be the principal determinant of ligand orientation. For a mechanism involving transit 
through the pantetheinate into the acyl channel, there is no obvious basis for 
discrimination in the orientation of the oxycarbonyl-disulfide group.  This and  the  
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presence of the carboxylate in the acyl channel argue against a threaded transit of the 
ligand into its final reactive position and for a lower energy pathway of entry. 
Reaction of 2 and 3 with the C112A and A246F mutants leads to no detectable tri-
modification of the protein (Figures 31, 32, 34, 35, and 36 b and c). For both inhibitors 2 
and 3, a major reaction product species was the unmodified mutated proteins.  These 
results contrast with those of the wild type FabH where there was no unmodified protein 
and the major species observed with either inhibitor was the tri-modified species. A 
striking observation from these ESI-MS studies is that the A246F mutant behaves like the 
C112A mutant with 2 and 3, but like the wild type mtFabH with 1. The presence of the 
phenylalanine mutation dramatically affects reaction of the active site cysteine, but only 
with inhibitors having two long chain hydrophobic arms.    
A co-crystallization of 3 with the A246F mutant revealed a complex with the A” 
fragment linked by a disulfide to Cys112 and lying in the acyl channel like the ligand 
complexes with wt mtFabH (Figure 37c). Fragment B”, which is observed in the 
pantetheinate channel of wt mtFabH, is absent in this A246F mutant and this channel 
remains blocked by the phenylalanine mutation (Figure 37c). Thus, while the ESI-MS 
results indicate that efficient reaction of the active site cysteine with 3 is affected by this 
mutation, the crystallization studies indicate that the reaction occurs. Formation of this 
product by entry of 3 through the pantetheinate channel, which is blocked, seems 
unlikely.  The most parsimonious hypothesis for its formation is that 3 binds to an ‘open’ 
form of the enzyme through interaction of its oxycarbonyl-disulfide group at the malonyl 
anion binding site; this orients A” in the acyl channel for disulfide exchange with 
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Fig. 37 
Figure 37. a. Structure of the product of compound 2 with mtFabH showing fragment A’ in the acyl channel disulfide linked to Cys112, 
and fragment B’ in the pantetheinate channel.  Arrows from A and P point to acyl channel and pantetheinate channel.   
b. Structure of the product of compound 3 with wt mtFabH showing fragment A” in the acyl channel disulfide linked to Cys112 and 
fragment B” in the pantetheinate channel. 
c. Structure of the product complex of compound 3 with A246F mtFabH showing fragment A” in the acyl channel disulfide linked to 
C112. The surface shape of the empty pentetheinate channel is shown blocked by F246. 
 
a                                                        b                                                                 c 
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Cys112, while B” extends into solvent from the ‘open’ form in lieu of binding in the 
pantetheinate channel, and dissociates when the thiol-disulfide exchange reaction occurs.      
 
5.5 Discussion:  
5.5.1 Unresolved aspects of M. tuberculosis FAS II enzyme mechanisms: 
The M. tuberculosis type II FAS pathway for synthesis of long chain (>C54) fatty 
acid precursors of the mycolic acid component of the bacterial cell wall 87 is a proven 
target for existing Tb treatments and offers other opportunities for development of new 
treatments.  Binding and transfer of long chain acyl reactants and products almost 
certainly require enzyme conformational changes and specific protein-protein 
interactions, some of which may be vulnerable points for therapeutic development.  In 
particular, it is not clear how some well characterized enzymes of this pathway can 
accommodate substrates of widely variable acyl chain length and how the protein 
components of the pathway interact.   
Characterization and structure determination of individual enzymes37,88-91 and 
acyl-carrier protein in this pathway92 provide evidence that conformational changes of the 
proteins play an important role in some individual steps.  For instance, conformational 
changes on substrate binding to InhA (FabI) provide an accessible acyl binding crevice to 
which a C16 thioester binds in a U-shaped conformation.93 For the reductive enzyme β-
ketoacyl reductase (MabA), an open and closed form of the enzyme have been observed 
and docking studies suggest that an L-shaped binding pocket in the open form can 
accommodate substrates up to C16,89 but it is unclear how physiological substrates with 
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acyl chains longer than C16 bind to either InhA or MabA. An acyl binding region for C10 
and C12 substrates in the condensing enzyme mtKasB has been identified and is U-
shaped.  While this binding pocket is larger and more occluded than the corresponding 
binding region of the E. coli FabB (which catalyzes the analogous reaction during 
palmitate biosynthesis in this microorganism),91 there is no data suggesting how the much 
longer physiological substrates bind to mtKasB.    
There is less information on protein-protein interactions both in the M. 
tuberculosis type II FAS and also with type I FAS, but there is evidence that such 
interactions are essential for mycobacterial viability.94,95 Formation of a type II FAS 
complex, possibly with some features resembling those in the type I FAS,96-98 is likely 
required to facilitate passage of the extremely long chain fatty acid substrates between 
enzymes.   
 To date there is no information on conformational changes or protein-protein 
interactions of mtFabH. The linear acyl binding pocket appears to be capable of accepting 
substrates only up to about C16 in length, (chapter 3) while experiments have shown that 
the enzyme can process C22 substrates.57 The crystal structure of mtFabH also raises the 
question of how substrate (and product) enter (and leave) the extended L-shaped binding 
site consisting of two long, tandem channels, which are roughly perpendicular to each 
other.  The distal, buried acyl-binding channel in the mtFabH structure appears accessible 
only through the pantetheinate channel, which opens to solvent.  However, a binding 
process in which lauroyl- or other long chain acyl-CoA is threaded first through the 
pantetheinate channel into the acyl channel seems implausible. 
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5.5.2 A model for substrate binding and product release in mtFabH   
An alternative to this substrate-threading model is a mechanism in which mtFabH 
exists in an ‘open’ conformational state, where both the acyl and pantetheinate binding 
channels are accessible. To test this hypothesis, we used active-site directed oxycarbonyl-
disulfide inhibitor ligands flanked on each side by alkyl or carboxyalkyl chains.      
Since existing crystal structures of both liganded and unliganded mtFabH are 
inferred to be in the ‘closed’ conformational state of the enzyme, we combined solution 
ESI-MS and crystal structure data to analyze the reaction pathways and product 
complexes of these inhibitor ligands with mtFabH.  These results provide evidence that 
these compounds do not bind to mtFabH by passage through the pantetheinate channel 
into the acyl channel. Inhibitor 1 efficiently enters the acyl-channel of the mtFabH A246F 
mutant, blocked in the pantetheinate channel, and the carboxylated C10 arm of compound 
2 binds in the acyl channel of wt mtFabH despite the inferred energetic obstacle to 
migration of a charged (or possibly protonated) group through two hydrophobic channels. 
These data argue strongly for an ‘open’ form of mtFabH that binds acyl substrates or 
inhibitors in a single step.     
A crystal structure of a disordered ecFabH63and recent kinetic data for inhibition 
of this enzyme with alkyl-CoA disulfide inhibitors83 support a model in which ‘open’ 
dimeric protein becomes ordered on binding of an acetyl-CoA substrate or methyl-CoA 
disulfide inhibitor. For the mtFabH there is no experimental crystal structure in a 
disordered or ‘open’ form, and a large structural change in the observed ‘closed’ crystal  
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Figure 38: (a)  Backbone ribbon model of the dimeric C112A mtFabH complex with lauroyl-CoA 
(color-coded space filling) bound in active sites of both monomers.  The putative flap that covers the 
extended L-shaped binding site is colored gold (front) in the right-hand (gray) monomer and magenta 
(back) in the left-hand (blue) monomer subunit. 
(b)  Surface figure of dimer in Figure 6a rotated approximately 90° about the horizontal axis 
showing the two flap covers (gold) of each of the two binding sites (defined by lauroyl-CoA (color 
coded space filling).  The flap in the blue left monomer is in the ‘closed’ conformation, thereby burying 
the lauroyl-CoA ligand; the flap in the gray right monomer is in the ‘open’ conformation (movement 
shown by arrow), opening the lauroyl-CoA binding site to solvent.            
 
 
Figure 16 
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structure would be required to provide direct access to the long hydrophobic acyl 
channel.  Inspection of the mtFabH structure reveals how the extended binding site of this 
enzyme could be exposed for concerted binding of long chain acyl-CoA substrates.  A 
single polypeptide segment (residues 183 – 209, ecFabH numbering) forms most of the 
top of the acyl channel and part of the top of the pantetheinate channel in mtFabH (Figure 
38a).  We note that this flap includes an insertion sequence in mtFabH relative to ecFabH 
that mediates intersubunit interactions in the mtFabH dimer.  The extremities of this 
polypeptide segment coincide with glycine residues (181 and 207) that are almost 
completely conserved across 5 FabH sequences.  Synchronized hinge motions at each of 
these glycines could raise this polypeptide flap to expose most of the substrate binding 
site of mtFabH to solvent and to the binding of substrates and ligands (Figure 38b).         
This proposed ‘open’ conformation of mtFabH provides an understanding of how 
both acyl-CoA substrates and the ligands 1-3 bind and react with the wild type enzyme 
and how 1 reacts with the A246F mutant. The proposed ‘open’ conformation of the 
mtFabH also offers a solution to the dilemma of how mtFabH utilizes substrates longer 
than palmitoyl-CoA (the maximum permitted chain length suggested by the ‘closed’ 
mtFabH structure). Exposure of the acyl binding channel would allow longer chains to 
extend outward from the channel, possibly interacting with the exposed hydrophobic 
underside of the opened flap in a modified ’closed’ conformation of mtFabH that is 
necessarily slightly different from that observed with lauroyl-CoA substrate (chapter 3). 
We propose that ordering or closing of the mtFabH on the substrate or inhibitor is 
required for efficient reaction with the active site cysteine and that this is why 2 and 3 
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react poorly with the A246F mutant. Reaction of this mutant with 3 results in loss of 
fragment B” whose only plausible position during this reaction is extended outward from 
the binding site, since the pantetheinate channel is blocked.       
In this model for acyl-CoA binding to mtFabH, the acyl-CoA reactants 
synchronously bind both arms of the substrate binding site and CoA product is released 
from the mouth of the pantetheinate channel in the first stage of the reaction.  In the 
second stage of the mtFabH reaction these different paths for substrate binding and 
product release would be reversed: the phosphopantetheine arm of ACP carrying the 
malonyl thioester would enter the mouth of the closed pantetheinate channel after CoA 
dissociation, and following decarboxylative condensation of malonyl-ACP, transition 
back to the ‘open’ form of the enzyme would permit egress of the hydrophobic 3-
ketoacyl ACP product.  This open form could also facilitate transfer of the long, 
hydrophobic acyl chain from the acyl channel binding site of mtFabH to a putative 
binding site on ACP. This latter step is supported by kinetic analyses of the complete 
mtFabH reaction that indicate an apparent difference in acyl group specificity when using 
E. coli vs M. tuberculosis ACP (ACPM),57 and by the structure of butyryl-ACP in which 
the acyl group is sequestered in a site on the ACP.99  We have observed ACP-dependant 
changes in substrate specificities of other FabH enzymes and kinetic data for inhibition of 
ecFabH on binding a MeSSCoA inhibitor are consistent with conformational transitions 
on malonyl-ACP binding.83   
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5.6 Conclusions 
In conclusion, the work described here demonstrates that large scale dynamic 
motions in mtFabH are likely required for ligand binding. Such conformational changes 
may be critical for the synchronization of binding and dissociation steps, not only in 
mtFabH but also in other enzymes of the FAS pathways, including transfers between the 
FASI and FASII components. They require consideration and may also offer alternative 
approaches in developing new therapeutics that target mycolic acid biosynthesis.    
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6. CHARACTERIZATION OF NAPHTHALENE-BASED COMPOUNDS AS 
NOVEL INHIBITORS OF FabH 
 
6.1 Summary 
A naphthalene based compound (A) (Figure 39) was previously identified as an 
effective inhibitor of pfFabH in a screening program at WRAIR (Walter Reed Army 
Research Institute). A number of structure based analogs were synthesized and found to 
be effective against purified pfFabH with IC50 values in the range of 0.027 µM to >500 
µM (unpublished data). In this study, we have tested these analogs against FabH from M. 
tuberculosis and reported a similar SAR with IC50 values ranging from 0.6 µM to 138 
µM. A comparison of the two sets of IC50 values was utilized to deduce a preliminary 
pharmacophore for this series of inhibitors.  
 
6.2 Introduction 
The emergence of multidrug resistance in recent times has shifted the impetus of 
anti-microbial research from lead discovery towards target discovery. β-ketoacyl-ACP 
synthase (FabH) is one such enzyme which, owing to its key role in type II fatty acid 
synthesis, has recently attracted considerable attention as a good anti-microbial drug 
target. Consequently, it has been characterized from a number of species including highly 
pathogenic microbes such as M. tuberculosis27,57,88,100 and S. pneumonia.101 Further, the 
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availability of crystal structures from various species has added enormously to the 
mechanistic knowledge of this enzyme and various research groups have directed 
significant efforts towards the design of selective FabH inhibitors in the recent past.  
Daines et al.102 utilized a combination of high throughput screening and homology 
modeling to identify a series of indole-based inhibitors found to be active against spFabH 
and ecFabH. These inhibitors were shown to bind non-covalently in the CoA/malonyl-
ACP pocket close to the active site triad. A computational search of National Cancer 
Institute (NCI) database for compounds structurally similar to thiolactomycin resulted in 
identification of several 1,2-dithiole-3-ones as potent inhibitors of both E. coli FabH and 
S. aureus FabH.81,103 In contrast to the indole-based FabH inhibitors the mode of binding 
of these inhibitors could not be determined. Recently, Nie et al. have used a structure-
based drug design approach which afforded a series of benzoylaminobenzoic acid 
compounds as potent inhibitors of E.  faecalis FabH.58 Some of these compounds 
demonstrated good antibacterial activity against Gram-positive and some Gram-negative 
organisms.  
Here we have explored the inhibitory activity of a series of naphthalene-based 
compounds, which were found effective against pfFabH and ecFabH (unpublished data), 
on mtFabH. The lead compound “A” (Figure 39) was initially identified in a screening 
effort by Division of Experimental Therapeutics branch of Walter Reed Army Institute of 
Research (WRAIR) for inhibitors of the P. falciparum FabH. This was later found to be 
active against FabH from E. coli and M. tuberculosis which led to the synthesis of 
fourteen analogs of inhibitor A (series 1-4; synthesis was carried out by Dr. 
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Alhamedsheh). These compounds were tested against purified pfFabH enzyme and the 
IC50 values are listed in Table 7 (pfFabH IC50 column). The compounds were also tested 
against chloroquine (CQ)- sensitive (D6) P. falciparum strain (pf D6 IC50 column). In this 
study, we have tested these compounds against purified mtFabH (mtFabH IC50 column) 
and deduced a generalized SAR based on IC50 values from the two FabHs. 
 
 
 
 
6.3 Results and Discussion 
The series of analogs 1-4 (see table 7) were tested against purified M. tuberculosis 
FabH using the ACPM independent assay described in chapter 2 and the IC50 values are 
listed in table 7 along with IC50 values for P. falciparum FabH and in-vivo inhibitory 
activity against chloroquine (CQ)- sensitive (D6) P. falciparum strain for comparison (pf 
D6 IC50 values). 
We initiated our SAR analysis with the variation of the ‘A’ ring. Removal of the 
methyl group from ring ‘A’ of our lead compound 1a led to ~ 4 times decrease in 
inhibitory activity in compound 1b in mtFabH. Further substitution of the methyl group 
to larger propyl and chloro groups and much bulkier phenyl group (compounds 1c, 1d 
Figure 39: Structure of the lead compound A. The rings are labeled as discussed in the text. 
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and 1g respectively) resulted in ~2-5 times decrease in inhibitory activity in mtFabH. 
Replacement of methyl to amine (1e) resulted in prominent 50-fold decrease in inhibitory 
activity in mtFabH while the relatively bulkier acetamide substitution (1f) had a meager 
effect on the activity. Total removal of ‘A’ ring of the lead compound 1a to 1h led to a 
small decrease in inhibitory activity indicating the non-essential nature of the ‘A’ ring. A 
very similar pattern in IC50 values on varying the ring “A” was noted for pfFabH 
enzymes with series 1. 
The SAR analysis of the ring “B” of the lead compound 1a was concentrated 
mainly on the importance of 1, 4 di-hydroxyls. Removal of the two hydroxyls (1j) 
resulted in > 200 fold decrease in inhibitory activity against mtFabH with an IC50 value 
of 138 µM. The oxidation of di-hydroxyls to di-keto groups (2a) resulted in a slight 
decrease in inhibitory activity but not nearly as drastic as their removal. We noticed a ~ 5 
times decrease in inhibitory activity on mtFabH and a ~ 20 fold decrease in inhibitory 
activity against pfFabH for compound 2a. Lastly, we tried the variation of the ‘C’ ring by 
removing the ‘C’ ring of compound 1a and 1f to 3a and 3b respectively. A complete loss 
of inhibitory activity against pfFabH enzyme and parallel 50-fold decrease in mtFabH 
IC50 values strongly suggested the necessity of ring ‘C’. Substitution of naphthalene-1,4-
diol (1a) to anthracene-1,4-diol (4a) resulted in a ~ 10 fold decrease in activity indicating 
the steric limit on ring ‘C’. 
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Compound R R1 R2 pfFabH IC50 (µM) pf D6 IC50 (µM) mtFabH IC50 (µM)
1a OH OH 0.07 24.5 0.61 ± 0.1
1b OH OH 0.2 90.5 2.84 ± 0.1
1c OH OH 0.07 102 3.09 ± 0.6
1d OH OH 0.12 9.7 3.61 ± 0.9
1e OH OH 115.9 16 28.96 ± 3.3
1f OH OH 0.03 14 3.76 ± 0.6
1g OH OH 0.4 15 1.49 ± 0.1
1h OH OH 0.03 20.3 3.53 ± 0.1
1i OH OH nd nd 3.53 ± 0.1
1j H H >500 31 138.1 ± 6.4
2a na na 1.4 21.4 1.99 ± 0.2
3a OH OH >500 14 34.35 ± 2.8
3b OH OH >500 24.5 31.38 ± 2.7
3c Cl OH 145.9 75 2.75 ± 0.3
4a OH OH 0.3 15.6 8.47 ± 1.6
Cl
H2N
H
N
O
H3C
HOOC
H
N
O
OHCl
 
 
Table 7: IC50 values of compounds 1-4 against pfFabH and mtFabH. The mtFabH IC50 
values determined in this study are highlighted.  
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The preliminary inhibitory analysis showed a clear similarity between the 
inhibitions of two FabHs by this series of compounds. The summary of SAR based on the 
above analysis is as follows. A wide range of substitution as well as the complete 
removal was well tolerated on ring ‘A’, which strongly suggests a large flexibility of this 
part of molecule. The di-hydroxyl groups on the ring ‘B’ are required for activity but can 
be replaced with di-keto groups too. The Ring ‘C’ was noted to be absolutely essential for 
activity as its absence led to drastic decrease in inhibitory activity in both enzymes. 
Finally, in-vivo activity was also tested in chloroquine (CQ)- sensitive (D6) P. 
falciparum strain and the results are shown in table 7. The “ineffective” in-vitro inhibitors 
(series 3 and 1j) showed comparable inhibition level (14 –75 µM) to the “effective” in-
vitro inhibitors (1a, 1c, 1h). The absence of any co-relation between the in-vivo and in-
vitro values strongly suggests that FabH is certainly not the sole enzyme target for this 
class of inhibitors. 
 
6.3.1 Mode of binding 
The available structural data depicts two distinct channels for ligand binding in all 
FabHs. The first channel, leading up to the active site Cys112
 
is shown to accommodate 
the pantetheinate arm of both CoA and ACP. The second channel, located at the distal 
end of the active site cysteine is shown to accommodate the variable acyl chain of the 
first substrate acyl-CoA. mtFabH contains the largest acyl pocket in FabH class of 
enzyme and consequently it can catalyze the condensation of the long acyl-CoAs (C6-C20 
CoAs) with malonyl-ACP to form the β-ketoacyl-ACP product. The inhibition pattern of 
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this series of compounds tested on mtFabH and pfFabH enzymes strongly indicates that 
these inhibitors would most likely bind in the common CoA/malonyl-ACP pocket 
considering the large difference in size of acyl pockets in two enzymes. Unfortunately, 
despite several co-crystallization attempts we were not able to determine the absolute 
mode of binding of these compounds in mtFabH enzyme. In addition, docking of the 
most potent analogs resulted in unconvincing results. Further biochemical studies such as 
mutational analysis are required to elucidate the mode of binding. 
 
6.4 Conclusions 
 A novel class of naphthalene based compounds is tested against clinically 
important mtFabH enzyme and the IC50 values were compared with pfFabH IC50. 
Although the inhibitory activity of the analogs based on the lead compound did not 
improve much, a basic pharmacophore was established based on available data. This 
pharmacophore can be further utilized to search for related structures in the vast chemical 
libraries available and also can be further improved by conventional chemical synthesis 
and QSAR technique. 
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7. Conclusions and Future directions 
 
 
1. M. tuberculosis FabH (mtFabH) is claimed to be a key enzyme for its proposed 
regulatory role in the biosynthesis of mycolic acid, an essential component of the 
mycobacterial cell wall responsible for imparting rigidity and virulence to the 
bacterium. The methods to assay mtFabH, thus far, have been very tedious and 
costly due to technical difficulties associated with physical separation of its 
substrate from its product. We have designed a simpler and more cost efficient 
assay in this study.  
This assay utilizes malonyl-CoA instead of malonyl-ACP and thus is the first 
ACP independent assay designed for mtFabH. We propose to utilize this assay in 
conjunction with the analogous malonyl-ACP-dependent mtFabH assay to 
investigate the molecular interaction between the mycobacterial acyl carrier 
protein (ACPM) and mtFabH. This study will involve mtFabH mutants mutated at 
key amino acid residues that are likely to be involved in interaction with ACPM. 
The relative condensation activity in ACP-dependent versus our ACP-
independent assay can help us understand the role of those residues in their 
interaction with ACPM.  
   
  
126 
 
2. Fatty acid enzymes in M. tuberculosis are responsible for synthesizing the long 
acyl chain component of the mycolic acids. Although mycobacterium enzymes 
share functional and structural similarities with FAS enzymes from other species, 
they have structural features, which make them unique. mtFabH is known to 
process much longer acyl-CoA substrates than its analogous enzymes in other 
bacterial species. In this study we solved the crystal structure of mtFabH with its 
substrate dodecanoyl-CoA. We observed that there is room for no more than four 
more carbons (maximum of hexa-decanoyl CoA) in the acyl pocket, which does 
not agree with its physiological substrate specificity. Although a possible 
hypothesis to resolve this paradox is set forth in chapter 5, a stable crystal 
structure of mtFabH complexed with C18-C24 CoA would be helpful in 
understanding the molecular dynamics involved in long acyl chain binding in the 
acyl pocket of mtFabH. In our previous attempts to obtain a co-crystal of mtFabH 
with tetradecanoyl-CoA or hexadecanoyl-CoA, we observed that a small impurity 
of dodecanoyl CoA in the preparation resulted in crystallization of density 
corresponding to doecanoyl CoA in the acyl pocket. We propose to achieve a pure 
preparation of longer acyl-CoAs (C18-C24 CoA) using the HPLC technique, and 
use it to prepare stable co-crystals with mtFabH. This will help us greatly in 
understanding the dynamics of substrate binding and possibly also the ligand 
trafficking in mtFabH.  
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3. Fatty acid biosynthesis (FAS) has been recently identified as an excellent drug 
target for bacteria in the wake of rising drug resistance. Although some clinically 
and commercially available compounds (eg isoniazid, triclosan) do target FAS, 
the full aptitude of this system is not yet utilized as many enzymes with no 
inhibitors in the clinical pipeline are likely to be good targets. FabH is one such 
enzyme with a proposed regulatory role in fatty acid biosynthesis in bacteria. 
While FabH from bacterial species such as E. coli is important for investigational 
purposes, FabH from clinical species such as M. tuberculosis and H.pylori hold 
more promise clinically. With only a handful of drugs that are effective against 
TB, and with the rise of MDR, it is imperative to develop new effective TB drugs. 
We plan to fully characterize mtFabH using the ACP dependent and ACP 
independent assay to have better understanding of the enzyme, which further can 
aid in discovery of novel anti-tubercular drugs.   
 
4. The ligand trafficking in mtFabH is one of the many unanswered questions which 
are critical to understanding the physiological functioning of this enzyme at the 
molecular level. In this study, we attempted to answer this question using a series 
of oxycarbonyl-disulfide ligands and a “CoA channel blocked” mtFabH mutant. 
We developed the first ever proof for mtFabH that large scale dynamic motion is 
important for its catalytic functioning. Further, we proposed a likely portal for 
substrate entry and product exit in mtFabH. This proposed flap formed by a single 
polypeptide segment (residues 183 – 209, ecFabH numbering) could expose most 
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of the acyl and CoA channels, thus serving as an entry and exit portal for 
substrate/product. We plan to investigate the proposed role of this polypeptide 
flap using a combination of mutational and other biochemical tools. An analysis 
of a series of mtFabH mutations at the hinge residues of this proposed flap -- for 
example, mutating the conserved glycine residues to more restrictive and bulkier 
residues like alanine or proline - should help us understand the role of these 
residues. 
 
5. In a previous study by Besra et al57, it has been observed that, under the 
experimental conditions used, the extent of acylation is found to be less than 25 
%. Further, the rate of acylation is surprisingly slower than the overall 
condensation rate of mtfabH. These results indicated a possible in-equivalency 
between the two monomers of the mtFabH dimer. In this study, we have shown 
for the first time that both mtFabH monomers can be fully acylated or alkylated 
by a mixture of acyl-CoA or alkyl-CoA disulfide. Surprisingly, ESI-MS studies 
showed that only dodecanoyl-CoA reacted with mtFabH from a mix of C6-C20 -
CoAs. This observation is in concordance with a previous one57 where longer 
substrates are processed more efficiently when cognate ACPM was utilized.  
These observations suggest a possible role of ACPM in priming of substrates 
and/or off-loading of products from mtFabH. We propose to investigate this 
particular aspect of mtFabH functioning using a variety of biochemical techniques 
including mutagenesis and mass spectrometry. 
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6. The assay developed in this study (chapter 2) was used to test a series of 
naphthalene based compounds which were identified in a library screening effort 
by Walter Reed Research Institute (chapter 6). This assay was also used to test a 
series of compounds which were found effective against ecFabH.104 The 
commercial availability of all the components of our assay and its simplicity 
makes it much more efficient to screen numerous potential inhibitors at one time 
without prior preparation of substrates and with minimal expenditure. We plan to 
further utilize our assay to speed the discovery and development of novel 
inhibitors of mtFabH as potential anti-tubercular agents. 
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Appendix 1 
A.1 Results 
A.1.1 Characterization of the E-I complex: 
A.1.1.1 Probing the nature of association between mtFabH and Inhibitors 1-3: 
 
We utilized a simple reversibility test to investigate the nature of association 
(covalent vs. non-covalent) between mtFabH and the inhibitors 1-3 (Figure X1). The 
enzyme was pre-incubated with excess of inhibitor at 37 ˚C for 60 minutes and the 
activity of this inhibited enzyme is checked using the standard assay to confirm the 
formation of E-I complex (> 95% inhibition; Figure X1 - “E~I complex” column). The 
control experiment is set up with untreated mtFabH under similar conditions. The 
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Figure X1: Probing the nature of association between mtFabH and I - The effect of dialysis and 
DTT treatment on condensation activity of mtFabH treated with inhibitor 1 (blue bars), 2 (maroon bars) 
or 3 (beige bars). 
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complex is then subjected to multiple dilution-concentration steps (a 1000 fold dilution 
factor is achieved as described in methods) to remove any excess or readily dissociable 
inhibitor from the enzyme and the residual enzymatic activity is indicative of reversibility 
of E-I complex. A non-covalent reversible E-I complex under these conditions would 
dissociate easily and the resultant freed enzyme would show restoration of activity while 
on the other hand, a covalently bound mtFabH in E~I complex would still show inhibited 
enzymatic activity. The experimental data showed that inhibitor treated mtFabH on 
dilution shows 1-2 % enzymatic activity (compared to Control; Figure above – “E~I – 
Dialysis” column) with all three inhibitors and thus suggested a non-reversible complex 
formation. This complex when treated with excess DTT (and subsequently dialyzed) 
resulted in restoration of 60-90% of activity compared to mtFabH control (Figure above - 
“E~I - DTT treatment” column; DTT treatment of mtFabH~Inhibitor 1, 2 and 3 showed 
59.9 %, 67.95 % and 85.65 % restoration of activity respectively) suggesting the 
formation of a disulfide linkage between mtFabH and the inhibitor series. Mass 
spectrometry and X-ray crystallographic studies as discussed in chapter 5 confirmed the 
formation of this disulfide linkage between the mtFabH cysteines and the inhibitor and 
also showed the exact nature of the complex formed.   
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A.1.1.2 Identification of the site of modification: 
To investigate the precise site of modification, we performed limited proteolysis 
of mtFabH - Inhibitor complex by trypsin followed by Reverse Phase-HPLC (RP-HPLC) 
fractionation of the resultant peptides to look for any modified peptide peaks. The control 
experiment consisted of untreated mtFabH digested in parallel under identical set of 
conditions. The modification of mtFabH peptide with the inhibitor would most likely 
alter its hydrophobicity and thus an appearance of new peptide peak or movement of 
existing one on the C18 matrix could implicate the modified peptide fragment. This 
peptide fragment could then be characterized to conclusively identify the nature and site 
of the modification.  
 
A.1.1.2.1 Standardization of Digestion conditions: 
We first started with the optimization of various digestion and HPLC conditions 
to ensure sensitivity and reproducibility in each run. The UV traces of undigested WT 
mtFabH and inhibitors (Control reactions) are shown in Figure X2. It was evident from 
the HPLC traces that the inhibitors bound tenaciously to the C18 column matrix and 
eluted at 100 % acetonitrile concentration (Figure X2b and X2c). The maximum 
concentration of acetonitrile required to elute all peptide fragments was found to be ~ 
60% and thus after a few HPLC runs 100 % acetonitrile was used to wash the column to 
ensure reproducibility. Other variables such as the amount of trypsin, time of digestion 
and the digestion conditions were also optimized and the results are shown in Figures X3, 
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X4 and X5. Based on the peptide profiles (HPLC traces), the digestion reaction was set to 
run under native conditions with 1:20 w/w of mtFabH / trypsin for 11 hrs as described in 
materials and methods. The digestion reaction was not run for extended period of time to 
preserve any labile association between mtFabH and inhibitors. Also, Dehydroascorbic 
acid was added to maintain the oxidizing conditions to maintain disulfide bonds.  
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Figure X2: Standardization of digestion conditions – Control reactions- RP-HPLC traces of a) 
undigested WT mtFabH, b) WT mtFabH + Inhibitor 1 and c) WT mtFabH + Inhibitor 2. The conditions 
used are described in the methods section. The UV detection wavelength is set at 204 nm. 
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Figure X3: Standardization of digestion conditions- trypsin / mtFabH ratio: RP-HPLC analysis of 
the peptide mixture obtained from trypsinolysis of WT mtFabH performed at a) 1 : 60 trypsin / mtFabH 
ratio and b) 1 : 20 trypsin / mtFabH ratio. 
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b 
Figure X4: Standardization of digestion conditions- Native vs Denatured: RP-HPLC analysis of peptide 
mixture obtained from trypsinolysis of WT mtFabH performed under a) Denaturing conditions with 
guanidium chloride and b) native conditions.  
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A.1.1.2.2 Tryptic digest analysis of the mtFabH- 1 complex: 
The comparison of the HPLC profile of trypsin digested mtFabH- 1 complex 
(test) and untreated mtFabH (control) showed the appearance of two distinct new peaks at 
34 and 41 minutes at 257 nm (Figure X6). To probe the reducibility of these new peaks 
(as suggested by the initial reversibility study - Figure X1) we incubated the control 
(untreated mtFabH – trypsin digested) and test (mtFabH-1 complex – trypsin digested) 
with DTT for 30 minutes and performed HPLC analysis on the resultant reduced peptide 
mixture. As evident from Figure X7, the peptide peak at 34 minutes disappeared on 
treatment with DTT suggesting the presence of a reducible disulfide bond while the 
second peak at 41 minutes stayed unchanged.  
Min 
 
Figure X5: Standardization of digestion conditions -time of digestion: RP-HPLC analysis of peptide 
mixture obtained from trypsinolysis of WT mtFabH for various digestion times. 
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Figure X6: HPLC analysis of tryptic peptides of mtFabH-Inhibitor 1 complex - The extended HPLC 
traces of peptide mixture obtained from trypsinolysis of - a) unmodified mtFabH - λ 204 nm b) mtFabH- 
inhibitor 1 complex - λ 204 nm c) unmodified mtFabH - λ 257 nm d) mtFabH-Inhibitor 1 complex - λ 257 
nm. The new peaks are indicated by asterisks. 
 
Minin 
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Min 
Figure X7: A Test of reducibility of new peaks from mtFabH-1 complex – Untreated and Inhibitor 1 
treated mtFabH peptides were incubated with DTT and subsequently analyzed by HPLC at 257 nm. Figure 
a) DTT reduced - untreated mtFabH tryptic peptides and b) DTT reduced – inhibitor 1 treated mtFabH 
tryptic peptides. The reducible peak is marked by an arrow and the non-reducible peak is marked by an *. 
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A.1.1.2.2.1 Primary sequence of the modified peptide and the residue of attachment: 
To further investigate the identity of these new peaks, we purified them on C18 
matrix and subjected them to Mass Spectrometric analysis in the Matrix Assisted Laser 
Desorption Ionization –Time of Flight (MALDI-TOF) mode. The masses (m/z) of the 
two peaks were determined to be 2599 and 1147 Da (34 and 41 minutes respectively) as 
shown in Figures X8b and X8c. The unique mass of the first peak (m/z 2599 Da) at 34 
minutes corresponded very well with the mtFabH peptide Val16-Arg36 of mass 2523 Da 
(envisioned by in-silico tryptic digestion of mtFabH) modified by fragment A (mass 77 
Da) of inhibitor 1. To test this hypothesis, we utilized the technique of “product ion 
analysis” in MALDI/TOF/TOF mode to analyze the two peptides. Only identical peptides 
give exactly the same “fingerprint ions” in this technique in mass spectrometric analyses. 
In this technique, the peptide in question is allowed to collide with neutral gas molecules 
(often Helium, nitrogen or argon) or air, which result in fragmentation of the peptide into 
smaller ions. The key sequence-specific fragment ions seen frequently are the “y-type” 
(formed when the charge is retained at C-terminus of fragment ion) and “b-type” ions 
(when charge is retained at N –terminus) which can be compared to any peptide to 
confirm their identity. Moreover, a modification at any particular residue will alter the 
sequence specific pattern of key ions thus potentially revealing vital information about 
the modification.  
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In order to obtain the proposed (unmodified) peptide fragment Val16-Arg36 of 
theoretical mass 2523 Da, we digested the untreated mtFabH with trypsin and performed 
direct MALDI/TOF analysis on the entire peptide mixture to search for the parent mass 
(Figure X9). The m/z of 2523 Da is selected and subjected to product ion analysis in 
MALDI/TOF/TOF mode (Figure X10a). In parallel, the new peak of 2599 Da mass at 34 
minutes was subjected to MALDI/TOF/TOF analysis (Figure X10b) and the 
fragmentation pattern of both peptides was compared. Comparing Figures X10a and 
X10b, the masses of “y” series ions were found to be exactly the same until ion y13 thus 
proving that the two peptides at hand were identical. An exact mass differential of 77 Da 
on ions “y15” (compared to theoretical fragmentation pattern shown in Figure X10) and 
“y16” (MALDI/TOF/TOF spectral data on both peptides) proved that Cys23 is modified 
with a 77 Da species. This data clearly identified the peak at 34 minutes in trypsin 
digested mtFabH- 1 complex is the “V16 V T N D E I C23 Q H I D S S D E W I Y T R36 “ 
peptide modified with fragment A of inhibitor 1 linked with Cys23. Additionally, the 
reducibility of this peak (as discussed above) also relates well to the proposed disulfide 
bond formation between the thiolate of Cys23 and fragment A of inhibitor 1.  
The second mass of 1147 Da (peak 2 at 41 minutes in Figure X6) did not correlate 
with any of the expected masses of the theoretical digested mtFabH peptides. This could 
be a result of aberrant (star) digestion or auto digestion (by trypsin) and thus was not 
explored further. 
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Figure X8: Identification of new peptides observed on trypsinolysis of Inhibitor 1 treated 
mtFabH. The extended HPLC trace (wavelength 257 nm) of peptide mixture obtained from 
trypsinolysis of mtFabH -Inhibitor 1 complex (a). The peptides are numbered and the MALDI-MS 
spectra of peak 1 (b) and peak 2 (c) are shown.  
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Figure X9: Search for proposed parent peptide Val16-Arg36 containing Cys23 (m/z 2523 Da). 
a) Theoretical mtFabH peptides on in-silico digestion with trypsin. The proposed parent peak of 
m/z 2523 (peptideT4) is underlined in red.  
  b) Experimental MALDI/TOF mass spectrum of peptide mixture obtained on trypsinolysis of 
untreated mtFabH. The arrow indicates the proposed parent peptide T4 of correct mass m/z 
2523 Da. 
   
  
154 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure X10: Relationship between peptide T4 of untreated mtFabH and HPLC peak 1 of 
mtFabH-1 digest: Tandem mass analysis of (a) proposed parent peptide T4 m/z - 2523 and (b) new 
peptide “1” m/z – 2599 (new peak at 34 minutes in figure 6). The series of y ions as labeled 
demonstrate that the sequence of the modified peptide is V16 V T N D E I C* Q H I D S S D E W I 
Y T R36) where asterisk denotes the residue modified. The ions y16 show a mass difference of 76.01 
Da (2070.9 Da versus 1994.89 Da) corresponding well with addition of fragment A of inhibitor 1. 
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b 
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A.1.1.2.3 Tryptic digest analysis of the mtFabH- 2 complex: 
A comparison of HPLC traces of trypsin digested mtFabH- 2 complex with Control 
(untreated mtFabH) showed the appearance of a new peak at 49 minutes (Figure X11). 
As outlined above, we probed the reducibility of this new peak by incubating it with DTT 
for 30 minutes followed by HPLC analysis of the reduced mixture (Figure X12). The 
disappearance of this “new” peak was consistent with a reducible bond, most likely a 
disulfide one between a mtFabH peptide and 2. 
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Figure X11: HPLC analysis of mtFabH-Inhibitor 2 tryptic peptides -HPLC fractionation (257 
nm wavelength) of the peptide mixture obtained from trypsinolysis of a) untreated mtFabH and b) 
mtFabH treated with excess of inhibitor 2. The new peptide is indicated by an asterisk. 
 
Min 
Figure X12: A Test of reducibility of new peaks from mtFabH-2 complex – Untreated and inhibitor 2 
treated mtFabH peptides were incubated with DTT and subsequently analyzed by HPLC at 257 nm. 
Figure a) DTT reduced - untreated mtFabH tryptic peptides and b) DTT reduced – inhibitor 2 treated 
mtFabH tryptic peptides. The new peak is reducible as marked by an arrow. 
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To unambiguously identify this new peptide, we purified it and the mass was determined 
to be 2739.4 Da by MALDI/TOF (Figure X13b). The mass value of 2739 Da 
corresponded very well with modification of Cys23 containing peptide of mass 2523 Da 
with fragment A’ (theoretical mass 217 Da) of 2 (refer to chapter 5, Figure 30 for 
fragment A’). Finally, the “product ion analysis technique” on “new” peak of m/z 2739 
and proposed parent mass of m/z 2523 revealed the identity of both peptides to be “V16 V 
T N D E I C23 Q H I D S S D E W I Y T R36 ” with fragment A’ of 2 covalently linked at 
Cys23 (Figures X14 a and b).  
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Figure X13: Identification of the new peptide peak observed on trypsinolysis of Inhibitor 2 
treated mtFabH. The HPLC traces (wavelength 257 nm) of peptide mixture obtained from 
trypsinolysis of mtFabH treated with Inhibitor 2 (a). The peaks are assigned by an asterisk and its 
MALDI-MS spectrum is shown in (b). 
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Figure X14: Relationship between peptide T4 of untreated mtFabH and new peak of mtFabH-2 
digest: Tandem mass analysis of (a) proposed parent peptide T4 and (b) new peptide peak in figure . The 
series of y ions as labeled demonstrate that the sequence of the modified peptide is V16 V T N D E I C* Q H 
I D S S D E W I Y T R36) where asterisk denote the residue modified. The ions y16 show a mass difference 
of 216 Da (2211.0 Da versus 1994.89 Da) corresponding well with addition of fragment A” of inhibitor 2. 
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A.2 Method: 
A.2.1 Reversibility studies:  
Reversibility studies were performed by the standard microcon dilution method. 
A solution of the mtFabH (100 µL of 2.6-5.2 µM solution in 50 mM sodium phosphate 
buffer, pH 7) was pre-incubated with inhibitor 1 (1.2 µL of 34 mM solution in MeOH; 
final inhibitor conc. 400 µM), inhibitor 2 or 3 (2.17 µL of 23 mM solution in MeOH; 
final inhibitor conc. 500 µM) for 60 min at 37˚ Celsius. Control experiments containing 
mtFabH enzyme were treated with 2.5 µl of MeOH (no inhibitor) in same manner. Two 
aliquots from each solution (1 µl each) were withdrawn and the mtFabH activity was 
determined under standard assay conditions. The remaining enzyme solutions were 
diluted to 500 µl with sodium phosphate buffer, pH 7.0 and concentrated to 50 µl using 
50 kDa molecular weight cutoff Microcon concentrator at 8000 rpm on a benchtop 
centrifuge. Another aliqout of 450 µl buffer was added and the Microcon step repeated 3 
times to obtain the final dilution factor of about 10,000 and enzyme activity was 
determined. The enzyme solutions were then treated with DTT (20 mM final 
concentration) for 30 min at room temperature, desalted against buffer solution to remove 
the excess DTT and the enzyme activity was determined. The enzyme concentration was 
determined by Bio-Rad protein assay in all aliquots and equal amounts of enzyme were 
used for all assays. 
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A.2.2 HPLC analysis of E-I complex: 
A solution of 100 µg native WT mtFabH in 50 µl sodium phosphate buffer 50 
mM, pH 7.0 was injected onto wide pore 250 X 10 mm C18 RP column, pore size 300 A˚, 
particle size 10 µM and the HPLC gradient was run by increasing the acetonitrile conc. 
from 0-60 % in 60 minutes at 2 ml/min. For controls, 1 mM solutions of inhibitors 1 or 2 
(1.6 µl of 34 mM inhibitor 1 or 2.3 µl of 23 mM inhibitor 2 were added to a final volume 
of 50 µl sodium phosphate buffer 50 mM, pH 7.0) were injected onto the C18 RP-HPLC 
column and the gradient increase of 1 % acetonitrile per minute was maintained until 100 
% acetonitrile (HPLC Buffer B) was achieved and then kept at buffer B for 40 minutes. 
For the selection of best conditions for further analyses, various digestion variables (e.g. 
native vs. denatured conditions, amount of trypsin to be used and time of digestion) were 
also standardized. A 0.74 mg/ml solution of WT mtFabH was treated with guanidium 
hydrochloride (final conc. 6 M) in Tris-HCl pH 8.5 and then desalted with sodium 
phosphate pH 7.0 using Hitrap desalting column. The protein was concentrated using 50 
kDa cutoff Microcon concentrator and then digested with trypsin for 6-8 hrs at 37 ˚C at 
200 rpm shaking(ratio 1 : 30 of trypsin : mtFabH) in parallel to native WT mtFabH. 
About 100 µg digested peptide mixture was injected onto the C18 column and analyzed as 
described above. The amount of trypsin to be used for digestion was determined by 
monitoring the extent of digestion at mtFabH : trypsin ratios of  60:1 and 20:1 w/w for 24 
hrs. To estimate an appropriate time for digestion, mtFabH was digested with trypsin 
(20:1 ratio w/w) at 37 ˚C and 200 rpm shaking and aliquots of 100 µg peptide mixture 
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were collected and analyzed at 3, 6, 9, 11 and 24 hours. The peptide traces were 
compared with 0 hrs and 24-hrs control (No trypsin added). 
A typical standardized trypsin reaction was performed as described below. A 
solution of mtFabH (~10uM) in sodium phosphate buffer 50 mM, pH 7.0, 2 mM 
dehydroascorbic acid was incubated with ~ 100 µM inhibitor (in methanol) for 1 hr and 
then desalted using either Pierce Desalting spin columns or Hitrap desalting columns. 
The concentration of methanol in final mixture was kept at or below 1%. Trypsin in 1 
mM HCl, pH 3.0 was added to bring the ratio of mtFabH: trypsin to be 20:1 w/w and the 
digestion mixture was kept at 37 ˚C for 9-11 hrs with shaking at ~ 200 rpm. A solution of 
above digested mixture was treated with 10 mM DTT (final conc.) at 37 ˚C for 1 hr and 
then analyzed by RP-HPLC as described below. An amount of 100 µg (typically) of total 
peptides was loaded onto widepore 250 X 10 mm C18 column, pore size 300 A˚, particle 
size 10 µM and the HPLC analysis was performed at a flow rate of 1 ml/min. The mobile 
phases used for HPLC analyses were: buffer A: 97 % water, 3 % acetonitrile, 0.01 % 
formic acid; buffer B: 97 % acetonitrile, 3 % water, 0.01 % formic acid. The gradient was 
started with 100 % buffer A for 5 minutes and then increased to 60 % B in 60 minutes. 
The concentration of buffer A was returned to 100 % in next 5 minutes and 20 minutes of 
100 % buffer A was allowed for equilibration step. The peptides were detected using dual 
wavelength UV detector set at 204 and 257 nm.   
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A.2.3 MALDI-MS and MALDI/MS/MS analysis: 
A.2.3.1 Sample preparation: 
A solution of 25 µM mtFabH in sodium phosphate buffer 50 mM, pH 7.0, 2 mM 
dehydroascorbic acid was incubated with 250 µM inhibitor 1 (in methanol) for 1 hr and 
then desalted using Pierce desalting spin columns. Trypsin in 1 mM HCl, pH 3.0 was 
added to bring the ratio of mtFabH: trypsin to be 20:1 w/w and the digestion mixture was 
kept at 37 ˚C for 11 hrs with shaking at ~ 200 rpm. The control reaction consisted of 
untreated mtFabH. Pierce Pepclean spin columns® (C18 resin column) were used to clean 
up the digested peptide samples for subsequent MALDI analysis. The following solutions 
were prepared as per manufacturer’s guidelines; activation solution: 50% acetonitrile; 
equilibration solution: 0.5% TFA in 5% acetonitrile; sample buffer: 2% TFA in 20% 
acetonitrile; wash solution: 0.5% TFA in 5% acetonitrile; elution buffer: 70% 
acetonitrile. A 15 µl aliquot from both trypsin digested control and test was taken out and 
mixed with 45 µl of sample buffer to bring the final concentrations of acetonitrile and 
TFA to be 5 % and 0.5 % respectively. The C18 resin was activated with 2 changes of 200 
µl activation solution and then equilibrated with 3 changes of 200 µl equilibration 
solution. The column was then loaded with 30 µg of peptide mixture and washed with 3-
4 changes of wash solution. Then 2 volumes of 10-µl elution solution were used to elute 
the peptide mixture, which was stored in - 20 ˚C until the analyses. 
 
 
 
   
  
163 
A.2.3.2 MALDI analysis conditions: 
The parent and product ion mass spectra of the tryptic peptides were acquired on a 
MALDI-TOF/TOF mass spectrometer equipped with a Nd:YAG laser (355 nm) operating 
at 200 Hz (4700 Proteomics Analyzer; Applied Biosystems, Foster City, CA). A 
minimum of 1500 shots was averaged for each spectrum. The instrument was externally 
calibrated in the positive ion reflector mode with a standard peptide mixture (4700 
Proteomics Analyzer calibration mixture; Applied Biosystems) by following the 
manufacturer’s instructions. The matrix solution was prepared by dissolving 2 mg of 
alpha-cyano-4-hydroxycinnamic acid (CHCA) in 1 mL of 50% acetonitrile/0.1% 
trifluoroacetic acid. An aliquot of the tryptic digest was mixed with the matrix solution at 
volume ratios of 1:3 to 1:10, depending on sample concentration. A 0.5 µl aliquot of the 
sample/matrix mixture was deposited onto a 192-well stainless steel MALDI target plate 
and allowed to air-dry. Before sample analysis by mass spectrometry, 2 microliters of 
cold water was applied on the deposits and removed within 1 min to remove water-
soluble salts and other impurities. Mass spectra were recorded in the positive ion reflector 
mode over an m/z range of 800-4000. The ions of interest were selected and subjected to 
CID (collision-induced dissociation) using filtered air as the collision gas and a collision 
energy set of 1 keV.  
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